愛齊科技 (ALGN) 2020 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Greetings, and welcome to the Align 4Q and Fiscal Year Earnings 2020 Call.

    各位好,歡迎參加 Align 2020 年第四季與全年財報電話會議。

  • (Operator Instructions)

    (接線員指示)

  • As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Shirley Stacy.

    提醒各位,本次會議將被錄音。現在我很榮幸介紹本次會議主持人 Shirley Stacy。

  • Thank you, Shirley. You may begin.

    謝謝你,Shirley。你可以開始了。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Good afternoon. Thank for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO; and John Morici, CFO.

    各位下午好。感謝各位加入。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同出席電話會議的有總裁兼執行長 Joe Hogan,以及財務長 John Morici。

  • We issued fourth quarter and full year 2020 financial results today via Globe Newswire, which is available on our website at investor.aligntech.com.

    我們今天透過 Globe Newswire 發布了 2020 年第四季與全年財務結果,可於我們網站 investor.aligntech.com 取得。

  • Today's conference call is being audio webcast and will be archived on our website for approximately 1 month. A telephone replay will be available today by approximately 5:30 p.m. Eastern Time through 5:30 p.m. Eastern Time on February 17. To access the telephone replay, domestic callers should dial (877) 660-6853 with conference number 13714292 followed by pound. International callers should dial (201) 612-7415 with the same conference number.

    今天的電話會議將以音訊網路直播,並將在我們網站上存檔約 1 個月。電話重播將於今日美東時間約下午 5:30 起提供,至 2 月 17 日美東時間下午 5:30 止。若要收聽電話重播,美國境內來電者請撥打 (877) 660-6853,輸入會議編號 13714292 後按井字鍵。國際來電者請撥打 (201) 612-7415,並輸入相同的會議編號。

  • As a reminder, the information provided and discussed today will include forward-looking statements, including statements about Align's future events and product outlook. These forward-looking statements are only predictions and involve risks and uncertainties that are described in more detail in our most recent periodic reports filed with the Securities and Exchange Commission, available on our website and at sec.gov.

    提醒各位,今天提供並討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件與產品展望的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容在我們最近向美國證券交易委員會提交的定期報告中有更詳細的說明,可於我們網站及 sec.gov 查閱。

  • Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statements. We have posted historical financial statements, including the corresponding reconciliations, including our GAAP to non-GAAP reconciliation, if applicable, and our fourth quarter and full year 2020 conference call slides on our website under quarterly results.

    實際結果可能有重大差異,Align 明確表示不承擔更新任何前瞻性陳述的義務。我們已在網站「季度業績」欄目下發布歷史財務報表及相應調節表(如適用,包括 GAAP 與非 GAAP 的調節),以及 2020 年第四季與全年電話會議簡報。

  • Please refer to these files for more detailed information. And with that, I'd like to turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?

    請參閱這些檔案以取得更詳細資訊。接下來,我想把電話交給 Align Technology 總裁兼執行長 Joe Hogan。Joe?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Thanks, Shirley. Good afternoon, and thanks for joining us. On our call today, I'll provide some highlights from the fourth quarter and full year, then briefly discuss the performance of our 2 operating segments, Clear Aligner and Systems and Services.

    謝謝你,Shirley。各位下午好,感謝加入我們今天的電話會議。我將先提供第四季與全年的一些重點,接著簡要說明我們兩個營運部門——透明矯正器(Clear Aligner)以及系統與服務(Systems and Services)的表現。

  • John will provide more detail on our financial results and share additional color on business trends. Following that, I'll come back and summarize a few key points and open the call to questions.

    John 將更詳細說明我們的財務結果,並補充更多業務趨勢的觀察。之後我會回來總結幾個關鍵重點,並開放提問。

  • Our fourth quarter was a strong finish to the year, with record revenues and volumes from both Invisalign aligners and iTero scanners, as well as increased gross margins, operating margins, EPS and cash flow. Our fourth quarter performance was driven by strong year-over-year growth across customer channels and regions and continued momentum sequentially.

    我們第四季為全年畫下強勁句點,Invisalign 隱形矯正器與 iTero 掃描儀的營收與出貨量皆創新高,同時毛利率、營業利益率、每股盈餘(EPS)與現金流也有所提升。第四季表現主要受惠於各客戶通路與各地區的強勁年增成長,以及連續季度的持續動能。

  • During the quarter, we achieved a major milestone in EMEA, with a shipment to our 2 millionth Invisalign patient that will be amplified with the EMEA-wide campaign that will launch next month. This milestone for EMEA reflects strong acceleration in Invisalign adoption and growth.

    本季我們在 EMEA 達成一項重要里程碑:出貨給第 200 萬位 Invisalign 病患;此里程碑將透過下月啟動的 EMEA 全區行銷活動進一步放大。EMEA 的這項里程碑反映 Invisalign 採用率與成長的強勁加速。

  • For Q4, total revenues were $834.5 million, up 13.7% sequentially and up 28.4% year-over-year. Q4 '20 Clear Aligner revenues of $700.7 million were up 12.9% sequentially and increased 28.9% year-over-year. In Q4, we shipped a record 568,000 Invisalign cases, an increase of 14.5% sequentially and 37.3% year-over-year.

    第四季總營收為 8.345 億美元,較前一季成長 13.7%,較去年同期成長 28.4%。2020 年第四季透明矯正器營收為 7.007 億美元,較前一季成長 12.9%,較去年同期增加 28.9%。第四季我們出貨創紀錄的 568,000 件 Invisalign 病例,較前一季增加 14.5%,較去年同期增加 37.3%。

  • Q4 reflects increased Invisalign adoption from both adults and teenagers, which are up 36.7% and 38.7% year-over-year, respectively. Our teen and mom-focused consumer campaign generated 77% year-over-year increase in unique visitors to our website and 76% increase in lead generation.

    第四季反映成人與青少年 Invisalign 採用率提升,分別較去年同期成長 36.7% 與 38.7%。我們以青少年與媽媽族群為主的消費者行銷活動,使網站獨立訪客數較去年同期增加 77%,潛在客戶(leads)產生量增加 76%。

  • In addition, Invisalign social media influencers like Charli D'Amelio, Marsai Martin, Christina Milian, Tisha Campbell-Martin, Rachel Zoe, Tiffany Ma and Tahj Mowry, continue to deliver exciting new content and increased engagement for the Invisalign brand with consumers and among their millions of followers.

    此外,Invisalign 的社群媒體影響者(influencers),如 Charli D'Amelio、Marsai Martin、Christina Milian、Tisha Campbell-Martin、Rachel Zoe、Tiffany Ma 與 Tahj Mowry,持續帶來令人振奮的新內容,並在消費者及其數百萬追隨者之間提升 Invisalign 品牌互動。

  • Our Digital Platform continues to gain traction as doctors' usage of iTero scanners increase. Our consumer and patient app was rolled out to more than 50 markets, resulting in more than a 2.5x increase in apps download and monthly active users in 2020 versus a year ago.

    隨著醫師使用 iTero 掃描儀的比例提高,我們的數位平台持續獲得市場動能。我們的消費者與病患 App 已推廣至超過 50 個市場,使 2020 年的 App 下載量與每月活躍用戶數相較一年前增加超過 2.5 倍。

  • Our patient feature usage continues to increase. For example, Invisalign virtual appointment was used 68,000 times. Our insurance verification feature was used 26,000 times and more than 30,000 patients enrolled in Invisalign Virtual Care in 2020. Our new consumer website was rolled out to more than 40 markets around the world and is driving increased effectiveness in lead generation. We also launched an improved new doctor recruitment website in the U.S. and Canada to support our digital conversion journey. This will be expanded to other markets in the next few months.

    病患端功能的使用量持續增加。例如,Invisalign 虛擬約診被使用 68,000 次;保險驗證功能被使用 26,000 次;且 2020 年有超過 30,000 名病患加入 Invisalign Virtual Care。我們全新的消費者網站已在全球超過 40 個市場上線,並提升潛在客戶開發的成效。我們也在美國與加拿大推出改版後的醫師招募網站,以支持我們的數位轉換旅程;未來幾個月將擴展至其他市場。

  • From a product perspective, growth was strong across the Invisalign portfolio, especially for noncomprehensive cases, including Invisalign Go and Invisalign Moderate. There are also more doctors engaging with us through the Aligned Digital and Practice Transformation, or ADAPT program, as more practices are moving towards digital practice optimization.

    從產品面來看,Invisalign 產品組合整體成長強勁,尤其是非全口(noncomprehensive)病例,包括 Invisalign Go 與 Invisalign Moderate。隨著更多診所朝向數位化診所優化轉型,也有更多醫師透過 Aligned Digital 與 Practice Transformation(即 ADAPT 計畫)與我們合作。

  • As you'll recall, ADAPT was piloted over 2 years ago and is being commercialized as a standalone service, providing the relevant workforce, clinical and marketing support to enable doctors to digitally transform their practices. In Q4, we shipped a record 77,000 Invisalign doctors worldwide, of which a record 7,300 were first time customers. We also trained over 6,400 new docs in Q4, including over 3,900 international doctors.

    如各位所知,ADAPT 於兩年多前開始試點,目前正以獨立服務形式商業化,提供相關的人力、臨床與行銷支援,協助醫師推動診所數位轉型。第四季我們全球出貨創紀錄的 77,000 位 Invisalign 醫師,其中創紀錄的 7,300 位為首次合作客戶。我們在第四季也培訓超過 6,400 位新醫師,其中包含超過 3,900 位國際醫師。

  • Q4 '20 System and Services revenues of $133.8 million were up 18% sequentially, driven by momentum in the Americas and EMEA, and up 26% year-over-year, reflecting strong growth in EMEA and Asia Pacific. Our results reflect continued strong uptake of the iTero Element 5D, the only inter oral scanner with caries detection, which is scaling rapidly across each region and represented approximately 1/3 of iTero volumes in Q4.

    2020 年第四季系統與服務營收為 1.338 億美元,較前一季成長 18%,主要受美洲與 EMEA 動能帶動;較去年同期成長 26%,反映 EMEA 與亞太地區的強勁成長。我們的結果反映 iTero Element 5D(唯一具備齲齒偵測功能的口內掃描儀)持續強勁的採用率;該產品在各地區快速擴張,第四季約占 iTero 出貨量的三分之一。

  • Innovation remains a cornerstone of our business. Today, we announced the availability of the iTero Element Plus series, which expands our portfolio of iTero Element scanners and Imaging Systems to include new solutions that serve a broader range of the dental marketplace.

    創新仍是我們業務的基石。今天我們宣布 iTero Element Plus 系列正式上市,擴充我們 iTero Element 掃描儀與影像系統(Imaging Systems)的產品組合,納入可服務更廣泛牙科市場的新解決方案。

  • The new iTero Element plus series of scanners and Imaging Systems builds on the success of the award-winning iTero Element family and offers in all the existing orthodontic and restorative digital capabilities, doctors have come to rely on, plus faster processing time and advanced visualization capabilities for a seamless scanning experience in a new sleek, ergonomically designed package.

    全新 iTero Element Plus 系列掃描儀與影像系統建立在屢獲獎項的 iTero Element 家族成功基礎上,提供醫師已仰賴的所有既有矯正與修復數位功能,並具備更快的處理時間與進階視覺化能力;以全新俐落且符合人體工學設計的機身,帶來無縫的掃描體驗。

  • We announced the launch of our next-gen ClinCheck Pro 6.0 proprietary treatment planning software with in-face visualization, and our Invisalign G8 improved predictability in our last earnings call, we announced. Their availability is being expanded across all regions.

    我們宣布推出下一代 ClinCheck Pro 6.0 專有治療規劃軟體,具備「臉部視覺化」(in-face visualization)功能;並在上一次財報電話會議中宣布 Invisalign G8 可提升可預測性。這些產品/功能的可用性正擴展至所有地區。

  • Further, we launched several enhancements to our treatment planning including improved final teeth position and auto segmentation. We also added several new features to our virtual care tool.

    此外,我們也推出多項治療規劃的強化功能,包括改善最終牙齒位置與自動分割(auto segmentation)。我們也為虛擬照護工具新增多項功能。

  • For the full year 2020, total net revenues were a record $2.5 billion, up 2.7% year-over-year. Clear Aligner revenues of $2.1 billion were up 3.7%, reflecting a record 1.6 million Invisalign shipments and growth of 7.9%. During the year, 30.3% of total Invisalign cases or nearly 0.5 million teens or younger started Invisalign treatment. This is up 11.5% from 2019. System and Services revenues were down slightly compared to 2019.

    2020 年全年,總淨營收創紀錄達 25 億美元,較去年同期成長 2.7%。透明矯正器營收為 21 億美元,成長 3.7%,反映 Invisalign 出貨量創紀錄達 160 萬件,並成長 7.9%。全年 Invisalign 總病例中有 30.3%(約 50 萬名青少年或更年輕患者)開始 Invisalign 治療,較 2019 年增加 11.5%。系統與服務營收較 2019 年略為下滑。

  • 2020 was a year unlike any other we've experienced. The COVID-19 pandemic and its impact have been life changing, marked by loss and separation, recovery and renewal, record highs and lows and significant milestones and accomplishments. Even at a time of huge disruption, we all had to adapt, evaluate priorities and develop new ways of doing things, both personally and professionally. Through it all, Align's priority has been the health and well-being of our employees and their families and our doctor customers and their staff, and that remains a constant.

    2020 年是我們所經歷過前所未有的一年。COVID-19 疫情及其影響改變了生活,伴隨著失去與分離、復原與新生、創新高與新低,以及重要里程碑與成就。即使在巨大干擾之下,我們都必須適應、重新評估優先事項,並在個人與職業層面發展新的做事方式。在這一切之中,Align 的首要任務一直是員工及其家人的健康與福祉,以及我們的醫師客戶與其員工的健康與福祉,而這一點始終不變。

  • Despite the swift onset of the pandemic and the uncertainty through 2020, we didn't halt our plans or change our strategy for continued growth. We completed the acquisition of exocad, accelerated our investments in marketing to create Invisalign brand awareness and drive consumer demand for our doctors' offices, accelerated new technology to market with virtual tools that enable our doctors to stay connected with their patients, provided PPE to those in need and supported doctors and their teams with online education and digital forms that went beyond products to help them navigate the uncertainty of the pandemic. As a result of our continued strategic focus and investments, we exited the year stronger than we started and 2021 is off to a great start.

    儘管疫情迅速爆發且2020年充滿不確定性,我們並未停止既定計畫,也未改變持續成長的策略。我們完成了對 exocad 的收購,加速行銷投資以提升 Invisalign 品牌知名度並帶動消費者對醫師診所的需求,加速將具備虛擬工具的新技術推向市場,使醫師能與患者保持連結;同時向有需要者提供個人防護裝備(PPE),並以線上教育與數位化表單支援醫師及其團隊,這些支援不僅限於產品本身,更協助他們在疫情的不確定性中前行。由於我們持續聚焦策略並投入資源,我們在年底時比年初更為強健,而2021年也有一個非常好的開局。

  • Now let's turn to the specifics around our fourth quarter, starting with the Americas. For the Americas region, Q4 Invisalign case volume was up 12.7% sequentially and up 34.1% year-over-year, reflecting increased utilization of Invisalign treatment for both orthodontic and GP channels. Our continued investments in digital marketing and sales programs and focus on market segmentation are helping drive strong growth of Invisalign clear aligners and iTero products.

    現在讓我們來看第四季的具體情況,先從美洲地區開始。就美洲而言,第四季 Invisalign 病例量較前一季成長 12.7%,較去年同期成長 34.1%,反映出在矯正專科(ortho)與一般牙科(GP)通路中,Invisalign 治療的使用率均有所提升。我們持續在數位行銷與銷售方案上投資,並聚焦市場區隔,正協助推動 Invisalign 隱形矯正器與 iTero 產品的強勁成長。

  • During the quarter, we continued offering sales initiatives to our doctor partners to help drive adoption of Invisalign and iTero products. The Bracket Buy Back - Switch program, which we launched in North America in Q2 '20, continues to drive conversions from wires and brackets to Invisalign clear aligners.

    本季期間,我們持續向合作醫師夥伴提供銷售推廣方案,以協助提升 Invisalign 與 iTero 產品的採用。自 2020 年第二季在北美推出的「Bracket Buy Back - Switch」計畫,持續推動醫師從傳統鋼線與托槽轉換至 Invisalign 隱形矯正器。

  • During Q4, and this program resulting -- has resulted in about 10,000 new cases, similar to Q3. We believe it's also causing a halo effect with patients switching from wires and brackets to Invisalign clear aligners with increased awareness of the benefits of Invisalign treatment and how it is less disruptive to their lives with the outcome of a beautiful smile through an Invisalign-trained doctor.

    在第四季,該計畫帶來的成果——約新增 10,000 個病例,與第三季相近。我們也認為,隨著患者對 Invisalign 治療優勢的認知提升,該計畫同時產生「光環效應」,促使更多患者從鋼線與托槽轉向 Invisalign 隱形矯正器;透過受過 Invisalign 訓練的醫師完成治療,不僅對生活干擾更小,也能達成美麗笑容的結果。

  • The Teen Awesomeness Centers programs, direct patients to Invisalign doctors who are experts at treating teens, and are seen as the go-to docs for treatment. We continue to see growth with Invisalign First for treatment in younger kids, driving increased comprehensive treatments within North America ortho channel.

    Teen Awesomeness Centers 計畫會將患者導向擅長青少年治療、並被視為治療首選的 Invisalign 醫師。我們也持續看到 Invisalign First 在較年幼兒童治療上的成長,帶動北美矯正專科通路中更高比例的全口(comprehensive)治療。

  • Latin American volume was also up year-over-year, led by strong growth in Brazil and Mexico. We believe the market for orthodontic treatment is huge in Latin America as we continue to grow our presence across the region. We saw increased utilization in the GP channel with Invisalign Go and the continued adoption of Moderate. The GP Accelerator program, designed exclusively for general practitioner dentists, provides an all-encompassing support plan based on practice needs that is centered around maximizing iTero integration, clinical support needs and implementing new marketing strategies.

    拉丁美洲的病例量亦較去年同期成長,主要由巴西與墨西哥的強勁成長帶動。隨著我們持續擴大在該區域的布局,我們認為拉丁美洲的齒顎矯正治療市場規模龐大。我們看到一般牙科(GP)通路中 Invisalign Go 的使用率提升,以及 Moderate 產品的持續採用。專為一般牙醫師設計的 GP Accelerator 計畫,提供依診所需求量身打造的全方位支援方案,核心在於最大化 iTero 整合、臨床支援需求,以及導入新的行銷策略。

  • We also see increased utilization with GP dentists that have enrolled in the iPro program as well as with doctors that have installed the iTero scanner. DSO utilization also increased and continues to be a strong growth driver, led by Heartland and Smile docs. For the full year, Americas Invisalign volume was up 3.6%.

    我們也看到已加入 iPro 計畫的 GP 牙醫師,以及已安裝 iTero 掃描儀的醫師,其使用率均有所提升。DSO 的使用率也增加,並持續成為重要的成長動能,主要由 Heartland 與 Smile docs 帶動。就全年而言,美洲地區 Invisalign 病例量成長 3.6%。

  • For international business, Q4 Invisalign case volume was up sequentially 6.7%, led by strong growth in EMEA as doctors returned from summer holiday season, offset somewhat by seasonally slower period in China. On a year-over-year basis, international shipments were up 41.1%, reflecting increases throughout both EMEA and APAC. For the full year, International Invisalign volume was up 13.3%.

    在國際業務方面,第四季 Invisalign 病例量較前一季成長 6.7%,主要由 EMEA 的強勁成長帶動,因醫師在暑期假期後回到工作崗位;但部分被中國季節性較慢的期間所抵銷。以年增率來看,國際出貨量較去年同期成長 41.1%,反映 EMEA 與 APAC 皆有成長。就全年而言,國際 Invisalign 病例量成長 13.3%。

  • For EMEA, Q4 volumes were up sequentially 47.9% and 48.3% on a year-over-year basis across all markets, with strong performance across both ortho and GP channels. Within the GP channel specifically, we saw acceleration in both utilization and shipments with Invisalign Go.

    在 EMEA,第四季病例量較前一季成長 47.9%,較去年同期成長 48.3%,涵蓋所有市場,且在矯正專科與一般牙科通路皆表現強勁。就 GP 通路而言,我們特別看到 Invisalign Go 的使用率與出貨量皆加速成長。

  • We also saw acceleration in both core and expansion markets with growth in our core markets led by Iberia, U.K. and France, along with continued growth in our expansion markets led by Central and Eastern Europe and the Benelux. We introduced the Ortho Recovery 360 program in EMEA last quarter to support our orthodontist as they started reopening their businesses. As of Q4, 3,200 orthodontists have enrolled in the program.

    我們也看到核心市場與擴張市場皆加速成長;核心市場的成長由伊比利亞、英國與法國領先,擴張市場則由中東歐與比荷盧地區(Benelux)帶動。上季我們在 EMEA 推出 Ortho Recovery 360 計畫,以支援矯正醫師在重新開業時的需求。截至第四季,已有 3,200 位矯正醫師加入該計畫。

  • During the quarter, we launched a Recovery II program with a refreshed website featuring all digital tools, growth programs and education events for EMEA doctors to support their relief efforts during COVID-19. We also held our Digital Innovation Forum at the beginning of December, where approximately 900 doctors, both ortho and GP, attended the 2-day forum event with keynotes on the digitization of dental practices. We also continued our digital excellence series of webinars launched by the iTero team.

    本季期間,我們推出 Recovery II 計畫,並更新網站,整合所有數位工具、成長方案與教育活動,供 EMEA 醫師使用,以支援其在 COVID-19 期間的復甦工作。我們也在 12 月初舉辦 Digital Innovation Forum,約有 900 位醫師(包含矯正專科與 GP)參與為期兩天的論壇,主題演講聚焦牙科診所的數位化。我們亦持續由 iTero 團隊推出的數位卓越(digital excellence)系列線上研討會。

  • Throughout the quarter, the following digital innovations were also launched across EMEA: Invisalign G8; ClinCheck Pro 6.0; and Invisalign Go Plus to help drive Invisalign clear aligner utilization. To support our GP doctors, we launched our GP Recovery 360 program last quarter, with over 2,700 GPs enrolled so far. We continue to offer online and on-demand education events, which reached over 15,000 GPs cumulatively. For the full year, EMEA Invisalign volume was up 12.6%.

    整個季度中,EMEA 亦推出以下數位創新:Invisalign G8、ClinCheck Pro 6.0,以及 Invisalign Go Plus,以協助提升 Invisalign 隱形矯正器的使用率。為支援 GP 醫師,我們上季推出 GP Recovery 360 計畫,目前已有超過 2,700 位 GP 加入。我們持續提供線上與隨選(on-demand)教育活動,累計觸及超過 15,000 位 GP。就全年而言,EMEA Invisalign 病例量成長 12.6%。

  • For APAC, Q4 volumes were down sequentially, 14.7%. Notwithstanding typical Q4 seasonality in China, following a strong Q3, we had strong growth in Japan and ANZ and Southeast Asia. On a year-over-year basis, APAC was up 30% compared to the prior year, reflecting continued strong growth across the region. We were pleased to see the growth in the adult segment with noncomprehensive cases with the Invisalign Moderate product in the GP channel.

    在 APAC,第四季病例量較前一季下滑 14.7%。儘管中國第四季通常具有季節性因素,且在第三季表現強勁之後,本季我們在日本、澳洲與紐西蘭(ANZ)以及東南亞仍呈現強勁成長。以年增率來看,APAC 較去年同期成長 30%,反映整個區域持續強勁的成長。我們也很高興看到成人族群在 GP 通路中,使用 Invisalign Moderate 產品的非全口(noncomprehensive)病例有所成長。

  • In the teen segment, we also saw an increase in utilization amongst Invisalign doctors, and we saw continued acceleration from Japan and ANZ. For the full year, APAC Invisalign volume was up 14.3%. Last year, we launched a new and improved digital learning environment for our doctors offering a comprehensive learning platform with role-specific content for orthos, GPS and their teams.

    在青少年族群方面,我們也看到 Invisalign 醫師之間的使用率提升,且日本與 ANZ 的成長持續加速。就全年而言,APAC Invisalign 病例量成長 14.3%。去年我們為醫師推出全新升級的數位學習環境,提供完整的學習平台,並為矯正專科、GP 及其團隊提供依角色區分的內容。

  • The improved functionality enables more online learning opportunities with spotlight features for what's trending now, recommended learning path based on doctors' experiences and expanded categories including digital treatment planning, comprehensive dentistry and team education.

    升級後的功能提供更多線上學習機會,包括「目前熱門」的焦點功能、依醫師經驗推薦的學習路徑,以及擴充的分類,涵蓋數位治療規劃、全方位牙科(comprehensive dentistry)與團隊教育。

  • For the year, over 127,000 doctors have accessed recorded lectures, completed self-paced learning modules and watched how-to videos with new certified doctors viewing more than 1.4 million pages of content. Among the ortho channel, over 47,000 unique users have engaged with the digital learning site, with an additional 80,000 unique users from the GP channel.

    全年共有超過 127,000 位醫師存取錄製講座、完成自訂進度的學習模組並觀看操作教學影片;新認證醫師瀏覽的內容頁面超過 140 萬頁。在矯正專科通路中,超過 47,000 名不重複使用者參與該數位學習網站,GP 通路另有 80,000 名不重複使用者。

  • As we've mentioned, we are seeing good adoption of the ADAPT program, which is an expert and independent fee-based business consulting service offered by Align to optimize clinics' operational workflow and processes to enhance the patient's experience and customer and staff satisfaction, which will, in turn, translate into higher growth and greater efficiencies for orthodontic practices.

    如我們先前所提,我們看到 ADAPT 計畫的採用情況良好。該計畫是由 Align 提供的專家且獨立的付費商業顧問服務,旨在優化診所的營運工作流程與流程管理,以提升患者體驗以及客戶與員工滿意度,進而為矯正診所帶來更高的成長與更佳的效率。

  • As a result, the ADAPT service -- participating process in Q4 improved profitability significantly after implementation. Our consumer marketing is focused on capitalizing on the massive market opportunity to transform 500 million smiles, educating consumers about the Invisalign system and driving that demand to our Invisalign doctor offices.

    因此,參與 ADAPT 服務——在第四季導入後,其獲利能力顯著提升。我們的消費者行銷聚焦於把握龐大的市場機會,目標是改變 5 億個笑容;同時教育消費者了解 Invisalign 系統,並將需求導流至我們的 Invisalign 醫師診所。

  • In Q4, we saw strong digital engagement globally, with more than a 77% increase in unique visitors, a 108% increase in doc locator searches and 76% increase in leads created, driven by our global adult- and mom-focused campaigns and teen-focused influencer content. Our U.S. mom/teen multi-touch multimillion-dollar campaign, with influencer-led YouTube videos, a mom-focused TV spot, a custom Twitch activation, and mega teen sensation, Charli D'Amelio, continued to perform very well and garnered 2.7 billion impressions in Q4. The statistics I shared previously speak to the successful reach of this marketing campaign is having to not only drive demand with consumers but also in educating them on the benefits of Invisalign treatment through a doctor's office.

    在第四季,我們在全球看到強勁的數位互動表現:不重複訪客增加超過 77%,醫師查找(doc locator)搜尋量增加 108%,建立的潛在客戶(leads)增加 76%;主要由我們面向成人與媽媽族群的全球行銷活動,以及面向青少年的網紅內容所帶動。我們在美國針對媽媽/青少年的多觸點、數百萬美元規模行銷活動——包含由網紅主導的 YouTube 影片、以媽媽為主的電視廣告、客製化 Twitch 活動,以及超人氣青少年明星 Charli D'Amelio——持續表現非常出色,並在第四季累計獲得 27 億次曝光。我先前分享的數據顯示,這項行銷活動的成功觸及不僅帶動消費者需求,也教育消費者透過醫師診所進行 Invisalign 治療的益處。

  • In Q4, we also launched media tests in the EMEA region, in the U.K., Germany and France, and in the APAC region in Australia and Japan. These have worked very well and resulted in more than a 6x increase in leads in EMEA and a 3x increase in leads in APAC. Several key metrics that show increased activity and engagement with the Invisalign brand are included in our Q4 quarterly presentation slides available on our website.

    在第四季,我們也在 EMEA 地區的英國、德國與法國,以及 APAC 地區的澳洲與日本啟動媒體測試。這些測試成效良好,使 EMEA 的潛在客戶數增加超過 6 倍,APAC 的潛在客戶數增加 3 倍。我們第四季簡報投影片(可於官網取得)中包含多項關鍵指標,顯示 Invisalign 品牌活動度與互動度的提升。

  • Align is always looking for new opportunities to reach consumers and be relevant to potential patients, wherever they work, live and play, which is why we announced the Invisalign brand is the official clear aligner sponsor of the National Football League, the NFL, and 11 NFL teams, including the Tampa Bay Buccaneers and Kansas City Chiefs.

    Align 一直在尋找新的機會,以觸及消費者並與潛在患者保持相關性,無論他們在哪裡工作、生活與休閒。這也是為什麼我們宣布 Invisalign 品牌成為美國國家美式足球聯盟(NFL)的官方透明矯正器贊助商,並同時贊助 11 支 NFL 球隊,包括坦帕灣海盜隊(Tampa Bay Buccaneers)與堪薩斯城酋長隊(Kansas City Chiefs)。

  • The NFL league partnership, designed to expand our reach with consumers, generated over 150 million impressions in 2020, helping to drive awareness of Invisalign clear aligner treatment at a national level, while the team agreements are designed to help us engage within key markets and connect consumers with doctors in those markets.

    此 NFL 聯盟合作夥伴關係旨在擴大我們對消費者的觸及,於 2020 年帶來超過 1.5 億次曝光(impressions),有助於在全國層級提升對 Invisalign 透明矯正治療的認知;而球隊合作協議則旨在協助我們在關鍵市場中深化互動,並將消費者與這些市場中的醫師連結起來。

  • For our Systems and Services business, Q4 revenues were up 18% sequentially due to higher shipments and services revenue. We continue to see momentum, with the iTero Element 5D Imaging System gaining traction in all regions with significant Element Flex sales in EMEA.

    在我們的系統與服務(Systems and Services)業務方面,第四季營收較前一季成長 18%,主要因出貨量與服務營收增加。我們持續看到動能,iTero Element 5D 影像系統在各區域皆獲得更多採用,且在 EMEA(歐洲、中東與非洲)地區 Element Flex 的銷售表現亮眼。

  • On a year-over-year basis, Systems and Services revenues were up 26% due to higher shipments and services. For the year, our System and Services total revenues were down 2.8% year-over-year, cumulatively over 3.1 -- 31.4 million orthodontic scans and 6.7 million restorative scans have been performed with iTero scanners.

    以年對年來看,系統與服務營收成長 26%,主要因出貨量與服務增加。全年而言,我們的系統與服務總營收年對年下降 2.8%;累計已使用 iTero 掃描儀完成超過 3,140 萬次矯正掃描與 670 萬次修復掃描。

  • For Q4, total Invisalign cases submitted with a digital scanner in the Americas increased to 84% from 79.5% in Q4 of last year. International scans increased to 73.7%, up 64.7% in the same quarter last year.

    第四季,美洲地區使用數位掃描儀提交的 Invisalign 總病例占比提升至 84%,高於去年第四季的 79.5%。國際地區的掃描占比提升至 73.7%,高於去年同季的 64.7%。

  • We're pleased to see that within the Americas, 94.8% of cases submitted by North American orthodontists were submitted digitally. We're also proud to share that iTero Element intraoral scanners are the winners of the 2020 Dentaltown Townie Choice award for Digital Impressioning category.

    我們很高興看到在美洲地區,北美矯正專科醫師提交的病例中有 94.8% 以數位方式提交。我們也很自豪地分享,iTero Element 口內掃描儀榮獲 2020 年 Dentaltown Townie Choice「數位取模(Digital Impressioning)」類別大獎。

  • Also during the quarter, the National Association of Dental Laboratories judging panel selected the iTero Element 5D as the winner of the 2020 Journal of Dental Technology WOW! Award. The award represents a recognition of our commitment to enhancing patient engagement and communications that support efficient laboratory production.

    此外,在本季期間,全國牙科實驗室協會(National Association of Dental Laboratories)的評審團選出 iTero Element 5D 為 2020 年《Journal of Dental Technology》WOW! Award 得主。此獎項代表對我們致力於提升患者互動與溝通、以支持高效率實驗室生產的肯定。

  • For exocad, during the quarter, we launched 2 of the largest software releases in history, DentalCAD and exoplan. Dental CAD 3.0 Galway includes over 90 new features and over 80 enhanced functionalities with significant improvements to reduce design time, such as Instant Anatomic Morphing. Exoplan 3.0 Galway includes over 40 new features and over 60 enhanced functionalities that support planning of edentulous cases, including the design of surgical guides. During the quarter, exocad also added 2 new large implant manufacturers as OEMs for exoplan in Brazil.

    就 exocad 而言,本季我們推出了史上規模最大的兩次軟體版本更新:DentalCAD 與 exoplan。DentalCAD 3.0 Galway 包含超過 90 項新功能與超過 80 項功能強化,並在縮短設計時間方面有顯著改善,例如 Instant Anatomic Morphing。Exoplan 3.0 Galway 包含超過 40 項新功能與超過 60 項功能強化,可支援無牙顎病例(edentulous cases)的規劃,包括手術導板的設計。本季 exocad 也在巴西為 exoplan 新增了 2 家大型植體製造商作為 OEM。

  • With that, I'll now turn it over to John.

    接下來我把時間交給 John。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Thanks, Joe. Now for our Q4 financial results. Total revenues for the fourth quarter were $834.5 million, up 13.7% from the prior quarter and up 28.4% from the corresponding quarter a year ago. For clear aligners, Q4 revenues of $700.7 million were up 12.9% sequentially and up 28.9% year-over-year, reflecting Invisalign volume growth in all regions, partially offset by lower ASPs.

    謝謝,Joe。現在來看我們第四季的財務結果。第四季總營收為 8.345 億美元,較前一季成長 13.7%,較去年同期成長 28.4%。在透明矯正器方面,第四季營收為 7.007 億美元,較前一季成長 12.9%,年對年成長 28.9%,反映 Invisalign 在各區域的量成長,但部分被較低的平均銷售價格(ASP)所抵銷。

  • Clear aligner revenues growth was favorably impacted by foreign exchange of approximately $5 million or approximately 0.8 points sequentially, and on a year-over-year basis by approximately $10.3 million or approximately 1.9 points. Q4 Invisalign ASPs were down sequentially $15, primarily due to increased revenue deferrals related to a higher mix of new cases versus additional aligners, partially offset by favorable foreign exchange and lower promotional discounts.

    透明矯正器營收成長在匯率方面亦受惠:較前一季約增加 500 萬美元(約 0.8 個百分點),年對年約增加 1,030 萬美元(約 1.9 個百分點)。第四季 Invisalign 的 ASP 較前一季下降 15 美元,主要因新病例相較於追加矯正器(additional aligners)的組合占比提高,導致遞延營收增加;部分被有利匯率與較低促銷折扣所抵銷。

  • As we mentioned last quarter, we did not implement a price increase in 2020, given our continued commitment to helping our customers in their recovery efforts during the pandemic.

    如同我們上季所提到的,鑑於我們持續致力於在疫情期間協助客戶復甦,2020 年我們並未實施漲價。

  • On a year-over-year basis, Q4 Invisalign ASPs decreased approximately $75, primarily due to our decision not to raise prices last summer, increased revenue deferrals for new cases versus additional aligners and higher promotional discounts, partially offset by favorable foreign exchange. As a result, clear aligner deferred revenue on the balance sheet increased $83 million sequentially and $195 million year-over-year and will be recognized as the additional aligners are shipped.

    以年對年來看,第四季 Invisalign 的 ASP 約下降 75 美元,主要因我們決定去年夏天不調漲價格、新病例相較於追加矯正器的遞延營收增加,以及較高的促銷折扣;部分被有利匯率所抵銷。因此,資產負債表上的透明矯正器遞延營收較前一季增加 8,300 萬美元,年對年增加 1.95 億美元,並將在追加矯正器出貨時認列。

  • Total Q4 clear aligner shipments of 568,000 cases were up 14.5% sequentially and up 37.3% year-over-year. Our System and Services revenues for the fourth quarter was $133.8 million, up 18% sequentially due to an increase in scanner sales and increased services revenues from our larger installed base and higher ASPs.

    第四季透明矯正器總出貨量為 56.8 萬例,較前一季成長 14.5%,年對年成長 37.3%。第四季系統與服務營收為 1.338 億美元,較前一季成長 18%,主要因掃描儀銷售增加,以及因安裝基數擴大與 ASP 提升而帶動的服務營收增加。

  • Year-over-year, Systems and Services revenue was up 26% due to higher scanner sales, services revenue and the inclusion of exocad's CAD/CAM services, partially offset by lower scanner ASPs. Imaging Systems and CAD/CAM services deferred revenue was up 30% sequentially and up 69% year-over-year, primarily due to the increase in scanner sales and the deferral of service revenues, which we recognize ratably over the service period.

    年對年而言,系統與服務營收成長 26%,主要因掃描儀銷售、服務營收增加,以及納入 exocad 的 CAD/CAM 服務;部分被較低的掃描儀 ASP 所抵銷。影像系統與 CAD/CAM 服務的遞延營收較前一季成長 30%,年對年成長 69%,主要因掃描儀銷售增加以及服務營收遞延;我們會在服務期間按期平均(ratably)認列該等營收。

  • Moving on to gross margin. Fourth quarter overall gross margin was 73.2%, up 0.4 points sequentially and up 0.5 points year-over-year. On a non-GAAP basis, excluding stock-based compensation expense and amortization of intangibles related to exocad, overall gross margin was 73.6% for the fourth quarter, up 0.3 points sequentially and up 0.7 points year-over-year.

    接著看毛利率。第四季整體毛利率為 73.2%,較前一季提升 0.4 個百分點,年對年提升 0.5 個百分點。以非 GAAP 基礎(排除股票基礎薪酬費用及與 exocad 相關的無形資產攤銷)計算,第四季整體毛利率為 73.6%,較前一季提升 0.3 個百分點,年對年提升 0.7 個百分點。

  • Clear aligner gross margin for the fourth quarter was 74.9%, up 0.1 points sequentially due to lower additional aligner volume, partially offset by higher warranty, other manufacturing costs and lower ASPs. Clear aligner gross margin was up 0.7 points year-over-year, primarily due to favorable product mix from increased iTero scanner absorption as a result of increased manufacturing volumes, partially offset by lower ASPs, higher warranty costs and other manufacturing costs.

    第四季透明矯正器毛利率為 74.9%,較前一季提升 0.1 個百分點,主要因追加矯正器出貨量較低;部分被較高的保固成本、其他製造成本以及較低的 ASP 所抵銷。透明矯正器毛利率年對年提升 0.7 個百分點,主要因製造量增加帶動 iTero 掃描儀吸收(absorption)提升,形成有利的產品組合;部分被較低 ASP、較高保固成本與其他製造成本所抵銷。

  • Systems and Services gross margin for the fourth quarter was 64.2%, up 2.2 points sequentially, primarily due to higher ASPs and increased manufacturing efficiencies from higher production volumes. Systems and Services gross margin was down 0.7 points year-over-year due to lower ASPs, higher freight and other manufacturing costs, partially offset by higher services revenue.

    第四季系統與服務毛利率為 64.2%,較前一季提升 2.2 個百分點,主要因 ASP 較高以及更高產量帶來的製造效率提升。系統與服務毛利率年對年下降 0.7 個百分點,原因為 ASP 較低、運費與其他製造成本較高;部分被較高的服務營收所抵銷。

  • Q4 operating expenses were $397.3 million, up sequentially 11.3% and up 23.8% year-over-year. The sequential increase in operating expenses is due to increased marketing and media spend and spending commensurate with business growth. Year-over-year, operating expenses increased by $76.5 million, reflecting our continued investment in sales and marketing, R&D activities and manufacturing operations.

    第四季營業費用為 3.973 億美元,較前一季增加 11.3%,年對年增加 23.8%。營業費用的季增主要因行銷與媒體支出增加,以及與業務成長相匹配的支出。年對年而言,營業費用增加 7,650 萬美元,反映我們持續投資於銷售與行銷、研發活動以及製造營運。

  • On a non-GAAP basis, operating expenses were $372.3 million, up sequentially 12.1% and up 23.4% year-over-year due to the reasons as described earlier. Our fourth quarter operating income of $213.2 million resulted in an operating margin of 25.5%, up 1.4 points sequentially and up 2.3 points year-over-year. The sequential and year-over-year increases in operating income and the operating margin are primarily attributed to higher gross margin and operating leverage.

    以非 GAAP 基礎計算,營業費用為 3.723 億美元,較前一季增加 12.1%,年對年增加 23.4%,原因如前所述。第四季營業利益為 2.132 億美元,營業利益率為 25.5%,較前一季提升 1.4 個百分點,年對年提升 2.3 個百分點。營業利益與營業利益率的季增與年增,主要歸因於較高毛利率與營運槓桿。

  • On a non-GAAP basis, which excludes stock-based compensation, amortization of intangibles related to exocad and acquisition-related costs, operating margin for the fourth quarter was 28.9%, up 0.9 points sequentially and up 2.5 points year-over-year. Interest and other income expense, net for the fourth quarter was a benefit of $1.4 million, primarily driven by favorable foreign exchange.

    以非 GAAP 基礎(排除股票基礎薪酬、與 exocad 相關的無形資產攤銷及併購相關成本)計算,第四季營業利益率為 28.9%,較前一季提升 0.9 個百分點,年對年提升 2.5 個百分點。第四季利息及其他損益(淨額)為收益 140 萬美元,主要由有利匯率所帶動。

  • With regards to the fourth quarter tax provision, our GAAP tax rate was 25.9%, which includes tax benefits of approximately $11 million related to adjustments in prior year's unrecognized tax positions. The fourth quarter tax rate on a non-GAAP basis was 14.5% compared to 16.6% in prior quarter and 20.9% in the same quarter a year ago. The fourth quarter non-GAAP tax rate was lower than the third quarter's rate, primarily due to the reasons previously stated.

    關於第四季所得稅費用,我們的 GAAP 有效稅率為 25.9%,其中包含約 1,100 萬美元的稅務利益,與調整前一年度未認列稅務部位(unrecognized tax positions)相關。第四季非 GAAP 稅率為 14.5%,相較前一季的 16.6% 以及去年同期的 20.9%。第四季非 GAAP 稅率低於第三季,主要原因為先前所述因素。

  • Fourth quarter net income per diluted share was $2, up $0.24 sequentially and up $0.47 compared to the prior year. On a non-GAAP basis, net income per diluted share was $2.61 for the fourth quarter, up $0.37 sequentially and up $0.85 year-over-year.

    第四季稀釋後每股淨利為 2 美元,較前一季增加 0.24 美元,較去年同期增加 0.47 美元。以非 GAAP 基礎計算,第四季稀釋後每股淨利為 2.61 美元,較前一季增加 0.37 美元,年對年增加 0.85 美元。

  • Moving on to the balance sheet. As of December 31, 2020, cash and cash equivalents were $960.8 million, an increase of approximately $345.3 million from the prior quarter, which is primarily due to higher cash flow from operations. Of our $960.8 million of cash and cash equivalents, $548.3 million was held in the U.S. and $412.5 million was held by our international entities.

    接下來談資產負債表。截至2020年12月31日,現金及約當現金為9.608億美元,較前一季增加約3.453億美元,主要由於營運活動帶來較高的現金流量。在我們9.608億美元的現金及約當現金中,5.483億美元持有於美國,4.125億美元由我們的國際實體持有。

  • Q4 accounts receivable balance was $657.7 million, up approximately 5% sequentially. Our overall days sales outstanding was 71 days, down approximately 6 days sequentially and down approximately 5 days as compared to Q4 last year due to strong cash collections. Cash flow from operations for the fourth quarter was $381.4 million. Capital expenditures for the fourth quarter were $53.2 million, primarily related to our continued investment in increasing aligner capacity and facilities. Free cash flow, defined as cash flow from operations less capital expenditures, amounted to $328.3 million. Under our May 2018 repurchase program, we have $100 million still available for repurchase of our common stock.

    第四季應收帳款餘額為6.577億美元,較前一季約增加5%。我們整體應收帳款週轉天數(DSO)為71天,較前一季減少約6天,且較去年第四季減少約5天,係因強勁的現金回收。第四季營運活動現金流量為3.814億美元。第四季資本支出為5,320萬美元,主要與我們持續投資以提升隱形矯正器產能及設施相關。自由現金流量(定義為營運活動現金流量扣除資本支出)為3.283億美元。依據我們2018年5月的庫藏股回購計畫,目前仍有1億美元可用於回購本公司普通股。

  • Before we move to the outlook, I would like to make a few comments on the full year 2020 results. In 2020, we shipped a record 1.6 million Invisalign cases, up 7.9% year-over-year. This reflects 13.3% volume growth from our international doctors and 3.6% volume growth from our Americans doctors.

    在進入展望之前,我想就2020年全年結果補充幾點。2020年,我們出貨創紀錄的160萬件 Invisalign 病例,年增7.9%。其中反映國際醫師端出貨量成長13.3%,以及美國醫師端出貨量成長3.6%。

  • Systems and Services volumes were down 12% compared to 2019, reflecting the impact of COVID-19 pandemic on equipment sales. Total revenue was a record $2.5 billion, up 2.7% year-over-year, with clear aligner revenues, a record $2.1 billion, up 3.7% year-over-year. 2020 Systems and Services revenue were $370.5 million, including exocad revenues from April 1, 2020 forward, compared to $381 million in 2019.

    系統與服務(Systems and Services)出貨量較2019年下降12%,反映COVID-19疫情對設備銷售的影響。總營收創紀錄達25億美元,年增2.7%;其中透明矯正器營收創紀錄達21億美元,年增3.7%。2020年系統與服務營收為3.705億美元(包含自2020年4月1日起的 exocad 營收),相較2019年的3.81億美元。

  • Full year 2020 operating income of $387.2 million, down 28.6% versus 2019, and operating margin at 15.7% versus 22.5% in 2019. 2019 operating income included a litigation benefit of $51 million and Invisalign store closures of $23 million for net benefit on operating margin of 1.1%.

    2020年全年營業利益為3.872億美元,較2019年下降28.6%;營業利益率為15.7%,相較2019年的22.5%。2019年營業利益包含5,100萬美元的訴訟利益,以及 Invisalign 門市關閉帶來2,300萬美元的利益,合計對營業利益率的淨正面影響為1.1%。

  • With regards to full year tax provision, our GAAP tax rate was negative 368.6%, which includes a onetime tax benefit of approximately $1.5 billion, net of current year amortization associated with the recognition of a deferred tax asset related to intra-entity sale of certain intellectual property rights resulting from our corporate structure reorganization completed in the first quarter of 2020.

    就全年所得稅費用而言,我們的GAAP有效稅率為負368.6%,其中包含約15億美元的一次性稅務利益(扣除當年度與確認遞延所得稅資產相關的攤銷),該遞延所得稅資產係源自我們於2020年第一季完成的公司架構重整所導致之集團內部出售特定智慧財產權。

  • Excluding the tax benefit related to our corporate structure reorganization and the related tax effects of stock-based compensation and other non-GAAP adjustments, the full year tax rate on a non-GAAP basis was 17.6% compared to 22% for 2019. 2020 diluted EPS was $22.41. On a non-GAAP basis, 2020 diluted EPS was $5.25. Free cash flow was $507.3 million for 2020, down $90.3 million versus 2019.

    排除與公司架構重整相關的稅務利益,以及與股份基礎給付及其他非GAAP調整項目相關的稅務影響後,2020年全年非GAAP有效稅率為17.6%,相較2019年的22%。2020年稀釋每股盈餘(EPS)為22.41美元;以非GAAP基礎計算,2020年稀釋EPS為5.25美元。2020年自由現金流量為5.073億美元,較2019年減少9,030萬美元。

  • Now let me turn to our outlook. Overall, we are very pleased with our Q4 performance and the strong momentum in our business, which has continued through January for both clear aligners and Systems and Services. As we discussed at our Investor Day in November, we are committed to making significant investments to drive growth, and we are seeing good return on these investments across all regions and customer channels.

    接下來談我們的展望。整體而言,我們對第四季表現及業務的強勁動能感到非常滿意,且此動能在1月於透明矯正器以及系統與服務兩大業務均持續延續。如同我們在11月投資人日所討論的,我們致力於進行重大投資以推動成長,且我們在所有地區與客戶通路都看到了這些投資帶來的良好回報。

  • These strong returns give us confidence to continue investing in sales, marketing, innovation and manufacturing capacity to accelerate adoption in a huge under-penetrated market. These investments, coupled with typically higher seasonal operating expenses as a percentage of revenue, are expected to result in sequentially lower operating margin percent in Q1 as we have historically seen.

    這些強勁回報讓我們有信心持續投資於銷售、行銷、創新與製造產能,以加速在龐大且滲透率仍低的市場中的採用。這些投資,加上通常季節性使營業費用占營收比重較高,預期將導致第一季營業利益率百分比相較前一季下降,這也是我們過去一貫所見的情況。

  • While the global operating environment surrounding the pandemic remains uncertain, we will continue to focus on what we can control, and we are confident in our ability to continue to execute. Our responsibility is to continue driving innovation and delivering on the needs of our customer, doctors and their patients.

    儘管疫情相關的全球營運環境仍具不確定性,我們將持續專注於可控事項,並對我們持續落實執行的能力充滿信心。我們的責任是持續推動創新,並滿足我們客戶、醫師及其病患的需求。

  • Over the past 24 years, Align has invested billions in technology, innovation, consumer marketing and demand creation to connect millions of consumers with our doctor customers. We will continue to invest in this business to drive demand and drive adoption of the Align Digital Platform, including manufacturing and operational expansion.

    過去24年來,Align已在技術、創新、消費者行銷與需求創造方面投資數十億美元,以連結數以百萬計的消費者與我們的醫師客戶。我們將持續投資此業務以推動需求,並推動 Align 數位平台(Align Digital Platform)的採用,包括製造與營運的擴張。

  • We will always be responsible. Just like we've done in the past, we make investments to drive growth and maximize ROI. We remain committed to our long-term target model of 20% to 30% revenue growth for clear aligners and Systems and Services and operating margin of 25% to 30%.

    我們將一如既往地負責任。正如過去所做的,我們進行投資以推動成長並最大化投資報酬率(ROI)。我們仍致力於長期目標模型:透明矯正器與系統與服務營收成長20%至30%,以及營業利益率25%至30%。

  • With that, I'll turn it back over to Joe for final comments. Joe?

    接下來,我把時間交回給Joe做最後的評論。Joe?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Thanks, John. The choices we made in 2020 to protect employees, support customers and press forward on our strategy for growth, were possible because of the strength of our balance sheet and the confidence we have in our business model.

    謝謝你,John。我們在2020年所做的選擇——保護員工、支持客戶並持續推進成長策略——之所以能夠實現,得益於我們資產負債表的強健,以及我們對商業模式的信心。

  • Our actions reflect our conviction in the enormous opportunity we have to transform smiles and change lives. With 15 million orthodontic cases starts annually and more than 500 million consumers who can benefit from a better smile, the market for digital orthodontics and restorative dentistry is massive and has been unleashed by the need for digital.

    我們的行動反映出我們堅信:我們擁有改變笑容、改變人生的巨大機會。每年約有1,500萬例正畸病例開始治療,且有超過5億名消費者可從更好的笑容中受益,數位正畸與修復牙科的市場規模龐大,並因對數位化的需求而被釋放。

  • In a macro sense, COVID-19 has accentuated the benefits and pervasiveness of the digital economy. From an Align standpoint, practices across every region are embracing digital treatment in new ways and more purposefully than ever before. Invisalign providers are using our virtual tools to minimize in-office appointments and deliver doctor-directed personalized treatment that meets the needs of the moment, and that will reshape the future of treatment.

    從宏觀角度看,COVID-19凸顯了數位經濟的優勢與普及性。就Align而言,各地區的診所正以前所未有的方式、且更有目的性地採用數位治療。Invisalign提供者正使用我們的虛擬工具以減少到院次數,並提供由醫師主導的個人化治療以符合當下需求,這也將重塑未來的治療模式。

  • Digital acceleration is not just around Invisalign treatment. It includes digital workflows around iTero scanners and general dentistry. Doctors tell us that the iTero scanner is central to their practice and their practice workflows, and it's key to driving digital treatment.

    數位加速不僅發生在 Invisalign 治療上,也包括圍繞 iTero 掃描儀與一般牙科的數位工作流程。醫師告訴我們,iTero 掃描儀是其診所及診所工作流程的核心,也是推動數位治療的關鍵。

  • We've also known this, iTero and now exocad are core components of the Align Digital Platform. Our integrated suite of unique proprietary technologies and services delivered as a seamless end-to-end solution for patients and consumers, orthodontists and GP dentists and lab partners.

    我們也早已了解這一點:iTero,以及現在的 exocad,都是 Align 數位平台的核心組成。我們整合的一套獨特專有技術與服務,為病患與消費者、矯正專科醫師與一般牙科醫師(GP)以及技工所合作夥伴,提供無縫的一站式端到端解決方案。

  • And particularly, we now have all the building blocks to create digital workflows, leveraging the combined power of Invisalign treatment, iTero scanners and exocad software to become more relevant to the GP market, which is critical to accessing the $500 million consumer opportunity.

    尤其是,我們現在已具備建立數位工作流程的所有基礎要素,能運用 Invisalign 治療、iTero 掃描儀與 exocad 軟體的綜合力量,提升我們在一般牙科(GP)市場的相關性,而這對於觸及5億名消費者的機會至關重要。

  • Align is a growth business with huge opportunities, but the environment remains uncertain due to COVID-19. Our plan is still to counter uncertainty by staying focused on our long-term strategy, living our values, supporting our employees and customers and keeping in mind the demand drivers we've identified over the past year.

    Align是一家成長型企業,擁有巨大的機會,但由於COVID-19,環境仍不確定。我們的計畫仍是以專注於長期策略來對抗不確定性,秉持我們的價值觀,支持員工與客戶,並牢記我們在過去一年所辨識的需求驅動因素。

  • The redirection of disposable income for many consumers; channel focus that allows us to reach and support a wider range of customers within each channel; and most importantly, the digital mindset that's taking hold with more and more of our customers and that we are supporting through innovative products and programs that can help support their digital transformation.

    包括:許多消費者可支配所得的重新分配;通路聚焦使我們能在各通路內觸及並支持更廣泛的客戶;以及最重要的——越來越多客戶正在形成的數位思維,而我們透過創新產品與方案來支持,協助其數位轉型。

  • We are not ignoring the reality of COVID-19 and how long it may be part of our lives. But we're also not going to stop driving the business forward for the good of the customers and their patients, our employees and our stakeholders.

    我們不會忽視COVID-19的現實,以及它可能在我們生活中存在多久。但我們也不會停止推動業務向前,為了客戶及其病患、我們的員工以及利害關係人的福祉。

  • In closing, I want to leave you with a few thoughts as we begin the new year. While there is considerable amount of turmoil in the world, our focus is on what we can control as a company. We have strong momentum. We'll stay focused on our strategic priorities, international expansion, patient demand and conversion, orthodontist utilization and GP dentist treatment.

    最後,在新的一年開始之際,我想留給各位幾點想法。儘管世界充滿相當程度的動盪,我們的重點是公司能掌控的事項。我們擁有強勁動能。我們將持續聚焦於策略優先事項:國際擴張、病患需求與轉換、矯正專科醫師使用率,以及一般牙科醫師(GP)治療。

  • In summary, we're very pleased with the fourth quarter and the full year results of 2020, during a remarkable year with events beyond our control as a result of COVID-19. It is during times such as this when having a solid strategy, combined with focused execution, can lead to outcomes that support growth, not only for Align's business, but also practice growth for Align's customers, which also leads to more and more Invisalign smiles.

    總結而言,我們對2020年第四季及全年業績感到非常滿意;在這個因COVID-19而發生許多超出我們掌控事件的非凡年度中,能取得這樣的成果尤為難得。正是在這樣的時刻,穩健的策略結合聚焦的執行,能帶來支持成長的結果——不僅是Align自身業務的成長,也能帶動Align客戶診所的成長,進而帶來越來越多的 Invisalign 笑容。

  • With that, turn it over to the operator and we'll take calls.

    那麼,接下來交給接線員,我們開始接聽提問。

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • Our first question comes from Ravi Misra with Berenberg Capital Markets.

    我們的第一個問題來自 Berenberg Capital Markets 的 Ravi Misra。

  • Ravi Misra - Analyst

    Ravi Misra - Analyst

  • So I just wanted to maybe start one. I'll let the others maybe talk about the quarterly trends. But one of the things that kind of stood out to me was, you're driving extremely strong volume growth amidst what's kind of a stable to slightly declining pricing environment. Just curious first, when do you think you'll be able to go back to the kind of prior model where you're able to take pricing? Is that still in the cards?

    我想我先問一個問題。其他人或許可以談談季度趨勢。不過有一點讓我特別注意到的是,在價格環境大致持平到略為下滑的情況下,你們仍推動了非常強勁的量成長。首先想請教,你們認為什麼時候能回到先前那種可以調漲價格的模式?這仍然在規劃之中嗎?

  • And then secondly, I think the teen market is an area that we've kind of always been looking at as the next leg of growth, the kind of huge market that's out there and you're talking about some of the conversion and the lead generations. Can you help us understand some of the conversion rates around the leads that you generate in terms of timing and how long this takes to get the ROI that is put in to the advertising that you're putting out there?

    第二點,我認為青少年市場一直是我們視為下一個成長動能的領域,是一個非常龐大的市場;你們也提到一些轉換與名單(leads)產生。能否協助我們理解,你們所產生的名單在轉換率方面(就時間點而言)大概如何?以及要多久才能讓你們投放的廣告取得投資報酬(ROI)?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Ravi, first of all, I guess, your first question is on average selling prices. We try to communicate this as strongly as we can is to keep your eyes on gross margin because we have huge mix, whether it's international mix or it's product mix, you see a lot of progress in iGo and products like Moderate and Invisalign First and those products. They carry actually lower average selling prices, but higher margins. And so you could often mix up on those things.

    Ravi,首先我想你第一個問題是關於平均銷售價格(ASP)。我們一直盡可能強烈地傳達:請把焦點放在毛利率,因為我們的組合變動很大,不論是國際組合或產品組合。你會看到 iGo 以及像 Moderate、Invisalign First 等產品的進展。這些產品的平均銷售價格其實較低,但毛利率更高。所以在這些因素上很容易因組合而產生混淆。

  • So I'd say, as we keep emphasizing, is don't be overly concerned about ASPs or focused on ASPs. Like John said, we didn't increase ASPs this year because we're interested in supporting our customers and making sure that this is difficult -- a really difficult transition for many practices right now and instituting a price increase just wouldn't have been responsible in that sense.

    所以我會說,正如我們持續強調的,不要過度擔心或過度聚焦 ASP。就像 John 說的,我們今年沒有提高 ASP,因為我們希望支持客戶,並確保在目前對許多診所而言這是一段非常艱難的轉型期;在這樣的情況下實施漲價,從責任角度來看並不合適。

  • But at the same time, we drove incredible productivity across the business, and we were able to show those kind of gross margins. So I hope you and the rest of the analyst community out there can actually see that. We've been talking about this for a few years, but actually taken place.

    但同時,我們在整個業務中推動了驚人的生產力提升,也因此能展現那樣的毛利率。我希望你以及其他分析師社群能看得出來。我們談這件事談了好幾年,但現在它確實發生了。

  • On the teen side, in the conversions from an advertising standpoint, I mean we come at this from a lot of different ways and a lot of different areas. And we -- if we're going to start teen season, you really have to start in February in the United States, and you have to really work through a lot of different aspects of social media. You advertise differently for moms than you do teens and different things like that.

    至於青少年端,從廣告角度來看轉換情況,我們是從很多不同方式、很多不同面向切入。而且——如果要啟動青少年旺季,在美國你真的必須從二月就開始,並且要在社群媒體的許多不同層面上運作。你對媽媽的投放方式和對青少年的投放方式不同,諸如此類。

  • So I can't give you a correlation coefficient in the sense of here we invest and how much we get back. But we understand as well as a business. We've been doing it for years. We understand the timing of it and more and more we become more specific on the social advertising pieces and how to implement that properly. And John, do you have anything you want to add?

    所以我沒辦法給你一個相關係數,說我們在這裡投資多少、能回收多少。但我們作為企業非常清楚這件事。我們做了很多年,了解其時間節奏;而且我們在社群廣告的各個環節上也愈來愈精準,知道如何正確執行。John,你有什麼想補充的嗎?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • No, that's just it. I mean, there's others that are in the equation. You have to reach the teen, as Joe described, and we talked about social influencers and so on. You have to reach the parents, and we try that and then also have the right formula with the doctor. So getting those 3 to think about going into treatment is really the key.

    沒有,就這樣。我的意思是,方程式裡還有其他因素。你必須像 Joe 所描述的那樣觸及青少年,我們也談到社群影響者等等。你也必須觸及家長,我們會這麼做;同時也要和醫師端有正確的配方。所以讓這三方都願意考慮開始治療,才是關鍵。

  • Ravi Misra - Analyst

    Ravi Misra - Analyst

  • Okay. Then maybe one last one, if I can ask one more. Just on the reopening and vaccination progress and kind of volumes, how are you guys kind of thinking about the consumer spending environment as the options that the patients going to have start increasing? I mean, is that going to require more investment here in the near term? Or do you think kind of where we're at a baseline where you've kind of gotten the ramp where things are starting to really click here with the advertisings that you're doing as is?

    好的。那如果可以的話,我最後再問一個。關於重啟與疫苗接種進展以及量的變化,隨著病患可選擇的活動開始增加,你們如何看待消費支出環境?我的意思是,短期內這會需要更多投資嗎?還是你們認為目前已經達到一個基準水位,廣告投放已經拉升到一個開始真正奏效的階段?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes, Ravi, it's a good question. I mean, look, we're always looking to maximize our return on investment. We talk about that to grow in this vastly under-penetrated market. In some countries, like in the U.S., it's just a matter of refining how we spend. We talk about the influencers, talk about NFL and other things.

    是的,Ravi,這是個好問題。你看,我們一直在尋求最大化投資報酬率。我們談過,為了在這個滲透率仍非常低的市場中成長。在某些國家,例如美國,更多是精進我們如何花錢。我們談到影響者,也談到 NFL 和其他項目。

  • And in other countries, we've really started spending some of that consumer advertising, and we see a great response, and we see a strong return. And those are areas that as we see that response, we see it turn into volume. Those are areas that will continue. So we're always looking at return on investment, and we'll find ways to be able to grow our volume that way.

    而在其他國家,我們確實開始投入一些消費者端廣告,我們看到很好的反應,也看到很強的回報。當我們看到那樣的反應並轉化為量時,那些領域就會持續投入。所以我們一直在看投資報酬率,也會找到方法用這種方式來推動量的成長。

  • Operator

    Operator

  • Our next question comes from Jon Block with Stifel.

    我們的下一個問題來自 Stifel 的 Jon Block。

  • Jonathan David Block - MD & Senior Equity Research Analyst

    Jonathan David Block - MD & Senior Equity Research Analyst

  • Joe, you mentioned 2021 is off to a great start. From 2015 to 2019, so I'm sort of isolating pre-COVID, management guidance for 1Q cases -- the guidance for 1Q cases were up pretty consistently, just low single digits off of what you did in the fourth quarter. And I guess where I'm going with this is, at a high level, what's the expectation for case growth sequentially? And I'm just trying to level set as the back part of 2020 likely benefited from some pent-up demand. So just how we should think about the trend line, if you would, into the early part of 2021?

    Joe,你提到 2021 年開局非常好。從 2015 到 2019 年,我算是把疫情前的期間單獨拿出來看,管理層對第一季病例數(cases)的指引——第一季病例數的指引通常只比第四季的實績高出低個位數的幅度,而且相當一致。我想問的是,從較高層次來看,對病例數的季對季成長有什麼預期?我試著校準一下,因為 2020 年後段可能受惠於一些被壓抑的需求。所以我們應該如何看待 2021 年初的趨勢線?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Jon, I'll let John have the specifics of it. I'd just tell you that January was a really strong orders quarter. So that momentum really continues.

    Jon,我讓 John 來講細節。我只想告訴你,一月的訂單非常強勁,所以那股動能確實延續下來。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • And look, Jon, I think as we've said, and we're controlling what we can control, making investments that help drive this business. We look at -- as Joe said, we felt really good about how we exited Q4. We saw that in January as well. And we don't want to guide, we specifically haven't because there's things that are outside of our control. And we'll leave that as it is. What we're trying to give you is kind of the latest information without projecting forward.

    Jon,你看,我想正如我們所說的,我們在掌控我們能掌控的事情,並做出有助於推動這門業務的投資。我們看——如 Joe 所說,我們對第四季的收官感覺非常好;一月也看到了同樣情況。我們不想提供指引,我們也刻意沒有,因為有些事情不在我們控制範圍內。我們就先維持這樣。我們想提供的是最新資訊,而不是向前預測。

  • Jonathan David Block - MD & Senior Equity Research Analyst

    Jonathan David Block - MD & Senior Equity Research Analyst

  • Okay. Fair enough. And I'll ask a quick 2-parter for the second one. EMEA was just gangbusters. I mean, I think it was up 48% off a 32% comp, shout out to markets. But anything to call out there? I mean, the number was huge.

    好的,可以理解。第二個我想快速問一個兩段式問題。EMEA 表現非常亮眼。我想年增 48%,而且是在 32% 的高基期之上,向各市場致意。不過那邊有什麼特別值得指出的嗎?這個數字非常大。

  • And then the second part is, teen up almost 40%, Joe, what do you think the underlying ortho market was growing? Where I'm going with this is just your conviction of short of maybe a type of inflection point, if you would, with teen share of share?

    第二部分是,青少年年增接近 40%,Joe,你認為整體矯正(ortho)市場的底層成長大概是多少?我想問的是,你對於青少年市占(如果可以這麼說,可能接近某種拐點)的信心如何?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Jon, I appreciate you bringing up EMEA. I mean, that was just an amazing performance, when you see that. I've been doing business in Europe since last 30 years, and you see growth like that by countries, it's amazing. And I think that's -- to me, that was really a story on the fourth quarter too, was the breadth of that growth. It wasn't just North America, it wasn't just Asia, it was -- it was deep, it was across segments, across GPs, across orthos.

    Jon,謝謝你提到 EMEA。那真的是非常驚人的表現,看到那樣的數字。我在歐洲做生意已經 30 年了,看到各國出現那樣的成長,真的很驚人。而且我認為——對我來說,第四季的一個故事就是成長的廣度。不只是北美,不只是亞洲,而是——很深、跨區域、跨客群,涵蓋一般牙醫(GPs)與矯正專科(orthos)。

  • So Jon, I'm not ready to talk about an inflection point. All I can say is when you think about, we had 77,000 doctors that ordered, that I talked about in my script, and then 7,200 to 7,300 more doctors, so that's 10% more doctors. That's a record for us, too. So when we see Invisalign, this digital treatment really catching on in a big way, and it's meaningful. Look, we're gearing up for it. We're obviously advertising to drive that demand, and we'll stay focused on just executing, Jon, right now.

    所以 Jon,我還不準備談什麼拐點。我只能說,當你想到我們有 77,000 位醫師下單——我在講稿裡提到過——然後又多了 7,200 到 7,300 位醫師,也就是醫師數增加了 10%。這對我們來說也是一個紀錄。所以當我們看到 Invisalign 這種數位治療以很大的方式被接受,而且是有意義的。你看,我們正在為此做準備。我們顯然也在投放廣告來推動需求,而我們現在會專注在執行上,Jon。

  • Operator

    Operator

  • Our next question comes from Steve Beuchaw with Wolfe Research.

    我們的下一個問題來自 Wolfe Research 的 Steve Beuchaw。

  • Stephen Christopher Beuchaw - Director of Equity Research

    Stephen Christopher Beuchaw - Director of Equity Research

  • I wanted to try to understand a little bit better the relationship between some of the things that you flagged, John, in your prepared remarks as it relates to deferrals and ASP. I certainly agree with the view that gross margins are really the critical metric. But I'm sure we're going to get a lot of questions about ASP tonight and over the next couple of days.

    我想更清楚理解一下,你在事先準備的發言中提到的一些事項——John——它們與遞延(deferrals)以及 ASP 之間的關係。我當然同意毛利率才是最關鍵的指標。但我確定今晚以及接下來幾天,我們會收到很多關於 ASP 的問題。

  • So I wonder if you could help us understand a little bit more deeply, one, why would we be seeing more deferred revenue here, both on aligners and on scanners? What's the relationship to ASP? And do we see that reverse?

    所以我想請你幫我們更深入地理解幾點:第一,為什麼我們會在這裡看到更多遞延收入,不論是在隱形牙套(aligners)還是掃描器(scanners)上?這和 ASP(平均售價)之間的關係是什麼?而我們是否也會看到它反向回轉?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. Steve, the basic way to think about this is as we look at our revenue, we've got revenue on a new case that we ship out, and there's a certain amount that you recognize on that shipment based on our rev rec. And then there's a certain amount for future aligners or future modifications that are needed, that will be deferred revenue.

    是的。Steve,基本的理解方式是:當我們看營收時,我們在出貨一個新病例(new case)時會有一筆營收,並且依照我們的收入認列(rev rec)規則,在該次出貨上會認列一定的金額。同時,對於未來可能需要的後續隱形牙套或未來的修改(modifications),也會有一部分金額會列為遞延收入(deferred revenue)。

  • And then you also get into your revenue, so those deferrals that you've made for maybe previous quarters or even previous year, that as they -- that doctor needs to use that additional aligners, you're going to get revenue for that.

    然後你也會在營收中看到:你先前可能在前幾季甚至前一年所做的那些遞延,當醫師需要使用那些額外的隱形牙套時,你就會把那部分轉成營收。

  • When you have a mix like we have, where there's much more, there's a demand for future volume for new cases, you get a mix where we just have a lot more as a percentage of new cases and that's what impacts ASPs. When we look at that from a margin standpoint, it's margin accretive.

    當你的組合像我們現在這樣,對新病例的未來量(future volume)需求更高時,你會看到一種組合效應:新病例占比更高,而這就是影響 ASP 的原因。從毛利角度來看,這是有助於提升毛利(margin accretive)的。

  • We're getting that as new cases. Many of the cases that we get back from a deferred revenue standpoint, where there's refinements, we just don't make as much margin on that. You get the deferred revenue, but you don't get as much of the margin. So there's those dynamics that we have. We saw just when you have a significant volume increase like we saw in our third and fourth quarter.

    因為我們是以新病例的形式取得這些收入。相較之下,我們從遞延收入回轉而來的許多病例,通常是精修(refinements),我們在那上面賺到的毛利就沒那麼高。你會取得遞延收入,但拿不到那麼多毛利。所以這裡面有這些動態。我們也看到,當出貨量像我們第三季和第四季那樣大幅增加時,就會出現這種情況。

  • Stephen Christopher Beuchaw - Director of Equity Research

    Stephen Christopher Beuchaw - Director of Equity Research

  • Okay. And then I wanted to follow-up about the GP channel. GP has been just gangbusters here lately. I wonder if I could try to understand that a little bit more deeply. One is, do you think it continues to grow at the sort of clip, relative to the ortho channel? Maybe two, do you think exocad has been a driver of incremental growth in that channel at this point?

    了解。接著我想追問 GP 通路。GP 最近表現非常強勁。我想更深入理解一下:第一,你認為它會以這樣的速度持續成長、相對於矯正專科(ortho)通路而言嗎?第二,你認為 exocad 到目前為止是否已經成為該通路增量成長的驅動因素?

  • And then lastly, should we think about the shift to DSO as being a variable one way or another? And I apologize for my kids screaming in the background.

    最後,我們是否應該把轉向 DSO 視為一個可能正向或反向變動的因素?也抱歉我小孩在背景尖叫。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • That's the life we live now. Steve, we understand it. It happens on like every call. From a GP channel standpoint, I mean, 3 years ago, when we first started segmenting in Europe and now we are doing in the states, and we do it all over the world. And then we introduced products like iGo that were specific to it.

    這就是我們現在的生活。Steve,我們理解的,幾乎每通電話都會發生。就 GP 通路而言,我是說,3 年前我們在歐洲開始做分群(segmenting),現在也在美國做,而且我們在全球各地都在做。然後我們也推出了像 iGo 這種專門針對 GP 的產品。

  • And just -- and a sales force that can communicate with GPs because it's a different conversation than with orthos. Steve, I can't tell you where it's going. But when we talk about that 500 million patients like I did in my script, that's where they are. And that's where you touch them. And it's a different -- it's not a big teen market. It's a lot of adults, but it has to have a workflow that's specific to a GP.

    以及——還有一支能和 GP 溝通的業務團隊,因為那和跟矯正專科(orthos)的對話是不同的。Steve,我無法告訴你它會走到哪裡。但當我在講稿裡提到那 5 億名患者時,他們就在那裡,而你就是在那裡接觸到他們。這是一個不同的——它不是一個很大的青少年市場,而是很多成人,但它必須有一套專門適用於 GP 的工作流程(workflow)。

  • And that's why we drive our products. It's why iTero is so important from a front-end standpoint. Your question on exocad is we think that's going to be a big GP driver for us. It's a big legitimate piece for us. But I don't think it's adding to volume right now. We're just rolling out these new products. We're just starting to integrate that kind of software code into iTero and into our programs, and that certainly will drive increased penetration in the future.

    這也是我們推動產品的原因。也因此 iTero 在前端(front-end)非常重要。你問到 exocad,我們認為那會是我們在 GP 端的一個重要驅動因素,是一個非常正當且重要的組成部分。但我不認為它現在就正在增加量。我們才剛在推出這些新產品,才剛開始把那類軟體程式碼整合進 iTero 以及我們的方案中,而這確實會在未來推動更高的滲透率。

  • Operator

    Operator

  • Our next question comes from Jeff Johnson with Robert W. Baird & Co.

    下一個問題來自 Robert W. Baird & Co. 的 Jeff Johnson。

  • Jeffrey D. Johnson - Senior Research Analyst

    Jeffrey D. Johnson - Senior Research Analyst

  • I wanted to start with -- I know it's tough, and maybe there's not even a way to do it. But any way to think about, especially over the last 2 quarters, how much of this patient volume has been backlog versus the Zoom effect versus true kind of accelerating penetration of clear aligners versus brackets and wires? Just is there any way to bucket or what -- any metrics you're looking at that tells you this is truly kind of that secular uptick we've all been waiting for versus backlog and some of the Zoom effect?

    我想先從——我知道這很難,甚至可能沒有辦法做到。但有沒有任何方式可以思考,特別是過去兩季,這些患者量(patient volume)有多少是來自積壓訂單(backlog),多少是來自 Zoom 效應(Zoom effect),以及多少是真正因為透明牙套相對於傳統托槽與鋼線(brackets and wires)的滲透率加速提升?是否有任何方法可以分類,或你們在看哪些指標,能告訴你這真的是我們一直在等待的那種結構性上升(secular uptick),而不是 backlog 和部分 Zoom 效應?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • I think as we get further and further from the second quarter, obviously, the backlog question becomes less and less as part of the noise of the structure, right? I feel a lot of analysts, Jeff, they wonder, hey, we had a great third quarter, obviously, and it was -- well, how much of that was really the second quarter that was rolled into the third. We really don't know what that was. We don't. And our doctors don't know it either as we talk to them.

    我認為,隨著我們離第二季越來越遠,顯然 backlog 的問題在整體結構雜訊中的占比會越來越小,對吧?我覺得很多分析師,Jeff,他們在想:嘿,我們第三季表現很棒,顯然——那其中有多少其實是第二季延後到第三季的?我們真的不知道。我們不知道。而且我們跟醫師聊的時候,他們也不知道。

  • The fourth, obviously, had less of that. And we really felt good about our orders in January, too. So I think we're really moving away from that question here soon. The number of docs, like I just quoted, with over 7,000 new docs ordering from us, 77,000 in total shows you the breadth of what's going on.

    第四季顯然就比較少那種情況。而且我們也對 1 月的訂單感到很不錯。所以我認為我們很快就會逐漸遠離這個問題。我剛才引用的醫師數據——有超過 7,000 位新醫師向我們下單、總計 77,000 位——顯示了目前發生的事情有多廣泛。

  • And what's really struck me in this entire thing too, Jeff, is really the -- this is not just the United States, this is all over the world. It's Latin America, it's APAC, it's tremendous growth in Japan and ANZ and traditional markets, in China, in Europe. So there's breadth to this and then the segments we talked about, both GPs and orthos. So look, there has to be backlog in the third quarter. There has to be some backlog in the fourth quarter, whatever, but we don't think that's the overriding story here.

    而且在整件事上真正讓我印象深刻的,Jeff,是——這不只是美國,這是全球各地。拉丁美洲、亞太(APAC)、日本與澳紐(ANZ)以及傳統市場都有非常強勁的成長,在中國、在歐洲也是如此。所以這件事有廣度,然後還有我們談到的各個分群,包括 GP 和矯正專科(orthos)。所以你看,第三季一定有 backlog,第四季也一定有一些 backlog,等等,但我們不認為那是這裡的主導故事。

  • Jeffrey D. Johnson - Senior Research Analyst

    Jeffrey D. Johnson - Senior Research Analyst

  • Yes, that's fair. And then one other kind of maybe more conceptual question. Just as I think about it through your advantages program, but are you seeing doctors that are the high-volume guys, the Platinum guys moving up to Diamond and Double Diamond? Is it the lower Bronze or Gold guys moving up to Platinum? Does it matter to you which it is?

    是的,這樣說合理。那再問一個可能更偏概念性的問題。當我透過你們的 advantages program 來思考時,你們是否看到那些高量的醫師——Platinum 等級的醫師升到 Diamond 和 Double Diamond?還是較低量的 Bronze 或 Gold 升到 Platinum?對你們而言是哪一種重要嗎?

  • But more importantly, conceptually, is it getting those low volume guys to really go all in here or the high-volume guys to convert completely to Invisalign? And I'm sure you're going to tell me it's a mix of both that, but just kind of what you're seeing would be helpful there on your own customer base.

    但更重要的是,從概念上來說,是讓那些低量的醫師真正全力投入,還是讓高量的醫師完全轉向 Invisalign?我猜你會告訴我兩者都有,但就你們在自家客戶基礎上看到的情況,能分享一下會很有幫助。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. You helped me answer that question, Jeff. It is a mix. But it is really broad. I mean we see it in the Bronze accounts and Golds and all the way to Diamond and Diamond Plus, and we see growth in all those segments.

    是的。你已經幫我回答了這個問題,Jeff。確實是兩者的混合。但它的覆蓋面非常廣。我是說,我們在 Bronze 帳戶、Gold,一直到 Diamond 和 Diamond Plus 都看得到,而且我們看到所有這些分群都在成長。

  • And I think it's kind of logical, right? The people that know how to digital are going to expand on it because digital really allows them to function in this COVID environment in a way that allows them fewer customer touches and they can actually carry on their practices in a normal way.

    而且我覺得這其實很合乎邏輯,對吧?那些懂得如何做數位化(digital)的人會在此基礎上擴張,因為數位化真的讓他們在這個 COVID 環境下能以更少的客戶接觸來運作,並且能以相對正常的方式持續經營診所。

  • Other doctors actually see the advantages of that. They have patients asking for them and they start to move toward a digital kind of a platform. So and overall, again, it's a breadth discussion. It's not just one area. It's not just one country, it's about one segment of the advantage program. We've just been seeing adoption across the board. And John, anything to add onto that?

    其他醫師也確實看到了這些優勢。他們有患者在詢問,他們就開始朝向數位平台(digital platform)移動。所以整體而言,再次強調,這是一個廣度的討論,不是只有某一個領域,不是只有某一個國家,也不是只有 advantages program 的某一個分群。我們看到的是全面性的採用。John,你有要補充的嗎?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • No. I'd echo this, the breadth. I mean, you have new doctors, like Joe said, 7,000 new doctors that come in with -- and want to do cases that come into our ecosystem and start cases. You see doctors who have done just a few cases really start to accelerate.

    沒有。我會呼應這個「廣度」。我是說,你有新醫師——就像 Joe 說的,有 7,000 位新醫師進來——想做病例、進入我們的生態系並開始病例。你也看到那些只做過少數病例的醫師開始明顯加速。

  • And then at the top of the pyramid, you have people that are doing a lot of cases and they do even more cases. So that's part of when we talk about the breadth of this growth and what makes us excited. And it's, like Joe said, not just a U.S. phenomenon. It's pretty much everywhere.

    然後在金字塔頂端,你有那些本來就做很多病例的人,他們做得更多。所以這也是我們在談這波成長的廣度、以及讓我們感到興奮的原因之一。而且就像 Joe 說的,這不只是美國現象,幾乎到處都是。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • And Jeff, the last thing you said is, do you care? Which I thought was kind of interesting is like we really don't care. We just want to serve the doctors who want to work with us. We see this market. We talk about how large this market is and how under-penetrated it is, and we just want to see wherever that growth is. That's great. Because on the low end, that's terrific, so on the high end, that's terrific. We set this company up to be able to service either side and to work well with them.

    而且 Jeff,你最後說的那點是:你在乎嗎?我覺得這很有意思——我們其實不在乎。我們只是想服務那些想和我們合作的醫師。我們看到這個市場,談到它有多大、滲透率有多低,而我們只想看到成長發生在任何地方。那都很好。因為在低端很棒,在高端也很棒。我們把公司打造到能同時服務兩端,並且能和他們良好合作。

  • Operator

    Operator

  • Our next question comes from Elizabeth Anderson with Evercore.

    下一個問題來自 Evercore 的 Elizabeth Anderson。

  • Elizabeth Hammell Anderson - Associate

    Elizabeth Hammell Anderson - Associate

  • I have this question. Obviously, the one of the many nice parts of the quarter was the scanner and CAD/CAM revenue. Can you talk a little bit about what you sort of see as sort of market growth there?

    我有個問題。顯然,本季眾多亮點之一是掃描器與 CAD/CAM 的營收。你們能否談談你們對那邊市場成長的看法?

  • Like where are you taking share? Is it in the GP? More in the ortho channel? Is it orthodontists adding their third scanner? Is it people finally saying, yes, I'll go digital? Obviously, the total number of cases submitted digitally was very high. Any other color you could provide there would be really helpful.

    例如你們是從哪裡取得市占?是在一般牙科(GP)嗎?還是更多在矯正通路?是矯正醫師添購第三台掃描器?還是大家終於說「好,我要數位化」?顯然,數位提交的總病例數非常高。若能再提供一些補充說明會很有幫助。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Elizabeth, it's -- you could work for us, okay, you kind of described exactly how that demand is. It's coming from all these different places. And a lot of it -- when you say where you're taking share, a lot of it is just analog share, there's so much of dentistry still just completely analog. They're still doing impressions and different pieces. And so it's -- the growth has been tremendous in that sense.

    Elizabeth,這個——你可以來我們公司上班了,好嗎?你幾乎把需求的樣貌描述得一清二楚。需求來自各個不同的地方。而且很大一部分——你問我們從哪裡取得市占,其實很多是從類比端拿回來的市占;牙科領域仍有非常多完全是類比作業,還在做印模以及各種流程。所以從這個角度來看,成長非常驚人。

  • Your question about orthodontists that start to move up and do a significant part of their practice being Invisalign, you see a scanner at every chair. And they use these things constantly. It's part of what they do.

    你提到矯正醫師開始往上提升,讓 Invisalign 佔其診所相當大一部分時,你會看到每張診療椅旁都有一台掃描器,而且他們一直在用,這已經是他們工作的一部分。

  • And what we see on the GP segment is the communication tool ends up being the scanner and the front of the scanner. Because in the past, they'd hold up a mirror and say, Can you see that second molar back there and you'd say, yes, but you really couldn't, right? Now you throw it on a screen, it's live.

    而我們在一般牙科(GP)看到的是,掃描器以及掃描器前端介面最後會成為溝通工具。因為過去他們會拿著鏡子說:「你看得到後面那顆第二大臼齒嗎?」你會說看得到,但其實你真的看不清楚,對吧?現在把它投到螢幕上,是即時的。

  • You can see exactly what's going on. It becomes an incredible patient communication tool in a sense of where is your dentition? What needs to be done? And it helps to convince patients of what the doctor wants to do and the validity of that kind of treatment.

    你可以清楚看到到底發生什麼事。某種意義上,它成為非常強大的病患溝通工具:你的齒列狀況如何?需要做哪些處置?它也有助於讓病患相信醫師想做的治療,以及那種治療的合理性。

  • So that -- this is where dentistry is going. And when you look at iTero, it is arguably the highest performing scanner in the world, the speed of it, the exactness of it, color rendering and also with NIRI technology, be able to see caries or cavities is a real benefit. Even the orthodontist, who want to make sure that before you start the treatment that, that dentition is in good enough shape to be the -- accept that kind of movement. So that's just -- this is the time for digitization inside of dentistry, and iTero plays a big role in that, and it front ends our Digital Platform.

    所以——牙科就是往這個方向走。當你看 iTero 時,它可以說是全球表現最頂尖的掃描器之一:速度、精準度、彩色呈現;再加上 NIRI 技術,能夠看到齲齒或蛀牙,這是很大的優勢。即使是矯正醫師,也希望在開始治療前確認齒列狀況足夠良好,才能——承受那樣的移動。總之——現在正是牙科數位化的時刻,iTero 在其中扮演重要角色,也作為我們數位平台的前端入口。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Especially in a COVID environment, given the fact that you don't want to have as much time for impressions and so on, and you want to be able to have something that's fast and really be part of that digital workflow, this iTero lends itself well.

    尤其在 COVID 的環境下,考量到你不希望在取模等流程上花太多時間,而且你希望有快速、能真正融入數位工作流程的工具,iTero 就非常適合。

  • Elizabeth Hammell Anderson - Associate

    Elizabeth Hammell Anderson - Associate

  • Okay. That's super helpful. And just -- like just a follow-up, more housekeeping questions. One, obviously, you announced the new products today, and I imagine that, that's something you'll be talking about as sort of the virtual Chicago mid-winter and what you would have discussed a lot of it IDS. Is there anything we should keep in mind in terms of the ramp of sort of new products or impact from IDS moving to the back half of the year?

    好的,這非常有幫助。再——追問幾個偏行政面的問題。第一,你們今天宣布了新產品,我想這也是你們在虛擬的芝加哥 Mid-Winter 會談到、以及原本在 IDS 會大量討論的內容。關於新產品的爬坡(ramp)或 IDS 延到下半年對你們的影響,有沒有什麼我們需要留意的?

  • And then on the other side, obviously, we saw your announcement about the move to Arizona. Sounds exciting. I just didn't know if that had any impact in terms of something we should model in on taxes or anything else, just to touch on that as well?

    另外一方面,我們也看到你們宣布搬到亞利桑那州,聽起來很令人期待。我只是想確認一下,這是否會對稅務或其他項目造成任何影響,讓我們在模型裡需要反映?也請順便談一下。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. I think I can answer the tax piece of it now. Really not a tax impact. It really came down to when we look at the campus that we have in San Jose and the expansion that we have from a technology center, we become space constrained. And so we want to keep that technology center, that innovation center in San Jose and expand that out and add more to help with that innovation and then moving to here in Tempe for kind of that head office just made sense to us.

    是的。我想我現在可以先回答稅務的部分。基本上沒有稅務影響。主要原因是:當我們看聖荷西的園區以及我們作為技術中心的擴建時,我們的空間變得受限。因此我們希望把技術中心、創新中心留在聖荷西並擴大規模,增加更多資源來支持創新;而把總部搬到坦佩(Tempe)對我們來說就很合理。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. And Elizabeth, on the new product pieces, keep in mind, we talked about we spend $0.5 billion a year on advertising and also new product development, you'll see a lot of new products. We don't pace ourselves on those introductions based on IDS. And that's why we, obviously, announced a new iTero scanner.

    是的。Elizabeth,關於新產品的部分,請記得我們提過:我們每年在廣告與新產品開發上投入 5 億美元。你會看到很多新產品。我們不會以 IDS 來安排這些產品的發表節奏。這也是為什麼我們——顯然——宣布了新的 iTero 掃描器。

  • We talked about the new 6.0 software that we have. A lot of changes to BiPAP, which is our final positioning aspect of dentition. We had the plus product from iGo, the in-face visualization. This is a digital business, and it requires constant iterations in products.

    我們也談到新的 6.0 軟體。我們對 BiPAP(也就是我們齒列最終定位的部分)做了很多改動。我們還有 iGo 的 plus 產品、臉部可視化(in-face visualization)。這是一門數位化的生意,需要持續不斷地迭代產品。

  • I mean -- and obviously, mid-winter and those things were great places to highlight it, but our innovation, we looked at it as agile not waterfall anymore. And then since waterfall used to be invent during the year, release one period of the year. More and more, you'll see us just monthly, just rolling out new products as we adapt to a more kind of an agile philosophy of development than a waterfall type of, if that's what you're asking, Elizabeth.

    我的意思是——而且顯然,Mid-Winter 以及那些活動是很好的展示平台,但我們的創新方式已經不再是瀑布式(waterfall),而是敏捷式(agile)。過去瀑布式是:一年內發明,然後在一年中的某個時點一次性發布。未來你會越來越常看到我們以每月為節奏推出新產品,因為我們正在採用更偏敏捷的開發理念,而不是瀑布式——如果你問的是這個的話,Elizabeth。

  • Operator

    Operator

  • Our next question comes from Richard Newitter with SVB Leerink.

    下一個問題來自 SVB Leerink 的 Richard Newitter。

  • Richard S. Newitter - MD of Medical Supplies & Devices and Senior Research Analyst

    Richard S. Newitter - MD of Medical Supplies & Devices and Senior Research Analyst

  • Just maybe to start off, the Switch program, which has clearly been extremely successful for you. I'm curious to know how much more runway there is associated program? And maybe if you could just comment on kind of how you're at least thinking about that from your internal modeling?

    我先從 Switch 計畫開始問,這個計畫顯然對你們非常成功。我想了解這個計畫還有多大的延伸空間(runway)?以及你們內部在建模時大概是怎麼思考的?能否評論一下?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes. Look, I think it has a huge amount of breadth to it. I mean, it's not just U.S. We started this in Japan actually years ago, introduced in the United States. And you think about -- it's just a great winner, detaching those wires and brackets from people's teeth, using Invisalign, understanding, like we said in our script, just how much more simple it is and better for people and comfortable for people to go with our product lines. So we think it's -- we have a lot of room to grow, and we're going to keep supporting it.

    是的。你看,我認為它的覆蓋面非常廣。它不只是美國。我們其實多年前先在日本開始,之後引進美國。你想想——這就是一個很棒的「贏家」:把鋼線和托槽從人們牙齒上拆下來,改用 Invisalign;並且如同我們在講稿裡說的,讓大家理解它有多簡單、對人更好、也更舒適,去選擇我們的產品線。所以我們認為——我們還有很大的成長空間,而且我們會持續支持它。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. And Rich, this is John. I mean, we are always looking at those types of promotions for an ROI. And in these cases, many cases, looking at it from an incremental standpoint, nothing could be more incremental than it was glued on to someone's teeth, and now they come off and they go to Invisalign. So we like those dynamics and it sends a great message.

    是的。Rich,我是 John。我們一直都會用投資報酬率(ROI)的角度來看這類促銷。在這些情況下,很多時候從增量(incremental)的角度來看,沒有什麼比「原本是黏在某人牙齒上的,現在拆下來改用 Invisalign」更具增量意義的了。所以我們喜歡這樣的動態,也能傳遞很好的訊息。

  • And those people who had wires and brackets on their teeth can talk about their experience with Invisalign. So there's a lot of positives to it. And as Joe said, it started in Japan, and we've seen great success in the U.S., and we look to other places as well.

    而且那些曾經戴著鋼線和托槽的人,也能分享他們使用 Invisalign 的體驗。所以這裡面有很多正面因素。正如 Joe 說的,它從日本開始,我們在美國也看到很大的成功,我們也會看其他地區。

  • Richard S. Newitter - MD of Medical Supplies & Devices and Senior Research Analyst

    Richard S. Newitter - MD of Medical Supplies & Devices and Senior Research Analyst

  • Got it. Helpful. And Joe, you said a few times how encouraging the trends have been in January. I'm just curious, understanding it's only one month. But all else equal, if the trends that you're seeing now were to hold kind of -- for a good portion of the year, where in your long-term -- kind of long-range plan of 20% to 30%, do you think you'd be falling towards the mid to upper end? I'm just trying to get a sense for kind of what you are thinking there?

    了解,很有幫助。Joe,你多次提到 1 月的趨勢令人鼓舞。我知道這只有一個月,但在其他條件不變下,如果你們現在看到的趨勢能夠大致維持——在今年相當一段時間——那麼在你們長期 20% 到 30% 的規劃區間裡,你覺得會更偏向中段到上緣嗎?我只是想了解你們的思考方向。

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Nice try, Rich. We're -- look, we're very committed to our long-term growth model, 20% to 30%. That's really all I can say right now. Rich, we're in a really uncertain environment. We're happy about January. And this is why we're not giving guidance. We're all living with volatility right now. We'll just continue to execute and keep our heads down. But we're committed to that 20% to 30% growth model that we've been talking about for several years.

    想得美,Rich。我們——你看,我們非常堅定地承諾我們的長期成長模型,也就是 20% 到 30%。我現在能說的就只有這些。Rich,我們正處在一個非常不確定的環境。我們對 1 月感到高興。這也是為什麼我們不提供財測指引。我們現在都在面對波動。我們會持續執行、專注把事情做好。但我們仍然承諾這個 20% 到 30% 的成長模型,這也是我們談了好幾年的。

  • Operator

    Operator

  • Our next question comes from John Kreger with William Blair.

    下一個問題來自 William Blair 的 John Kreger。

  • John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services

    John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services

  • Just sticking with that answer, you were, obviously, above that in terms of volumes in the -- in the fourth quarter. How do you feel about your ability to deliver on that if the order flow were sustained in terms of fabrication and fulfillment? How do those metrics holding up at this point?

    延續剛才那個回答,你們在第四季的量——顯然——是高於那個區間的。若訂單流量能持續,你們在製造與履約(fabrication and fulfillment)方面交付的能力如何看?目前這些指標表現如何?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Our supply chains, we try to keep ahead in that sense. So I feel we have adequate plans and capacity right now to be handling a surge in demand.

    我們的供應鏈在這方面會盡量超前部署。所以我覺得我們目前有足夠的規劃與產能,來應對需求的激增。

  • John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services

    John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services

  • Great. Okay. And then, John, I think you've talked about in the past, a reasonable assumption is kind of a flattish ASP and I realize there's a lot of puts and takes. But is that still a reasonable kind of planning thing for us or are you guys thinking less on the pricing front and therefore, maybe more of a downward trend over the coming year?

    很好。好的。接著,John,我記得你過去提過,一個合理的假設是ASP大致持平,我也知道其中有很多拉鋸因素。但這對我們來說仍然是一個合理的規劃假設嗎?還是你們在定價面上認為會更弱,因此未來一年可能會呈現較明顯的下行趨勢?

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • It's tough because it really becomes kind of the end result because if you have more primary cases, as I spoke, compared to secondaries, you can get to see some of these impacts in ASPs. I think in general, there's not a significant change that we would expect in some of the mix or some of that pricing. So that being said, you wouldn't expect too much fluctuations in ASPs. But like I said, it depends on that demand that comes forward from our doctors.

    這很難,因為它其實會變成一種最終結果:如果如我所說,你的初次病例(primary cases)相較於二次病例(secondaries)更多,你就會看到ASP受到一些影響。我認為整體而言,我們不預期在產品組合或定價方面會有顯著變化。也就是說,你不會預期ASP有太大的波動。但如我所說,這取決於我們醫師端所帶來的需求。

  • John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services

    John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services

  • Got it. Okay. And then one more. Joe, so in a typical year, we'd assume kind of teens would be big in Q3 and adults would be bigger in Q4. Is that same sort of seasonal pattern likely do you think in '21, given what we know now? Or would you expect kind of teen order flow to be more kind of spread evenly throughout the year?

    了解。好的。再一個問題。Joe,一般來說,我們會假設青少年在Q3會比較強,成人在Q4會比較強。以目前我們所知道的情況來看,這種季節性模式在2021年你認為仍然可能成立嗎?還是你會預期青少年的訂單流會更平均地分散在全年?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Yes, John, we don't know. But I'd tell you, it did -- it became muted this year. Obviously, we saw a much stronger fourth quarter in the United States in teens than we saw -- it's that you normally see from a season standpoint, it gets continued. So I think all of us are expecting summer and fall months as COVID has started to retreat a little bit. That might take us back to the patterns that we had before, but I don't think it's going to be binary. I really don't.

    是的,John,我們不知道。但我可以告訴你,今年這個季節性確實——變得比較不明顯。顯然,我們在美國看到青少年在第四季的表現強得多,超過——你從季節性角度通常會看到的水準,而且這種趨勢延續了下來。所以我想我們都在期待,隨著COVID開始稍微退去,夏季和秋季月份可能會讓我們回到以前的模式,但我不認為會是非黑即白的結果。我真的不這麼認為。

  • I think this could have changed the pattern. We're going to have to just ride the curve here and see how it goes. But we'll continue to advertise through this, execute on the plays that we talked about in our scripts, and we really feel confident we can continue to drive significant teen demand.

    我認為這可能已經改變了模式。我們只能順著曲線走,看看情況如何。但我們會持續投放廣告,執行我們在講稿中談到的策略,而且我們非常有信心能持續帶動顯著的青少年需求。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Operator, we'll take 1 or 2 more questions, please.

    接線員,請再讓我們回答1到2個問題。

  • Operator

    Operator

  • Our next question comes from Jason Bednar with Piper Sandler.

    下一個問題來自Piper Sandler的Jason Bednar。

  • Jason M. Bednar - VP & Senior Research Analyst

    Jason M. Bednar - VP & Senior Research Analyst

  • Congrats on another really strong quarter. I appreciate all the details you discussed. Maybe building off some of the real-time commentary you shared in your prepared remarks there, Joe. Just curious if you can expand on what you're seeing in January from maybe a utilization perspective? Maybe in the context of where we were October through December? Any notable call-outs in January from like a geographic perspective or teens or adults?

    恭喜又交出一個非常強勁的季度。也感謝你們分享的所有細節。或許延續你在事先準備的發言中提到的一些即時觀察,Joe。我想請你再多談談你們在1月從使用量(utilization)的角度看到什麼?也許可以放在10月到12月的背景下比較。1月在地理區域、青少年或成人方面,有沒有什麼值得特別指出的?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • I think the call out, Jason, really is just the breadth of it, really. There wasn't any geography in particular that dominated or it was just in segment 2, GP and ortho continue to be strong. So when you exit a year and you enter a new year, you're obviously glue to that month to see, especially in a business like this, what the momentum is. And we just see a continuation of the strong momentum that we had in the fourth quarter that's -- John, anything you can add on...

    Jason,我認為真正值得一提的是它的廣度,真的。沒有任何特定地區特別主導;而且在第2個分部(segment 2)方面,全科(GP)和齒顎矯正(ortho)仍然很強。所以當你結束一年、進入新的一年時,你當然會緊盯那個月份,尤其是像這樣的業務,要看動能如何。我們看到的是第四季強勁動能的延續——John,你有什麼可以補充的嗎……

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • Yes. I think the breadth of it is my note on this that we have across geographies between GP and orthos. And what we've described is a lot of doctors that are higher up in the tier, they are continuing to do a lot of volume. And then a lot of new doctors that come in, that come in with cases in hand, and we can get them to start the Invisalign system into our digital ecosystem. So that continued from Q4 into Q1.

    是的。我對此的重點也是它的廣度:跨地區、在全科與矯正醫師之間都很廣。我們所描述的是,很多層級較高的醫師仍在持續做大量病例;同時也有很多新醫師加入,而且一進來就帶著手上的病例,我們可以讓他們開始使用Invisalign系統並進入我們的數位生態系。因此,這種趨勢從Q4延續到了Q1。

  • Jason M. Bednar - VP & Senior Research Analyst

    Jason M. Bednar - VP & Senior Research Analyst

  • Okay. That's helpful, guys. And then just focusing on China here just for a quick moment. There wasn't a great deal of discussion, probably less in this call than maybe any other call in recent memory, in China, in particular. But I appreciate the seasonality that happens here in the fourth quarter. But maybe just wondering if you can expand on what you're seeing with your business in the clear aligner market in China specifically and maybe compare that against some of your other APAC markets?

    好的,這很有幫助。接著我想快速聚焦一下中國。這次對中國的討論不算多,可能比近期任何一次電話會議都少。不過我理解第四季的季節性因素。但我想請你們再談談,在中國的隱形矯正器市場,你們的業務目前看到什麼?以及和其他亞太市場相比如何?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • We felt good about our growth in China, 26% for the quarter overall. China is -- we see shutdowns periodically, issues in Shanghai or different places. The Chinese are pretty draconian. I'd use -- the move is when they see COVID, they move pretty quickly. The public hospitals have been throttled to a certain extent on elective procedures.

    我們對中國的成長感到滿意,本季整體成長26%。中國——我們會不時看到封控,例如上海或其他地方出現狀況。中國的措施相當嚴格;我會說——他們一旦看到COVID,就會很快採取行動。公立醫院在選擇性療程方面在某種程度上被限縮了。

  • So -- but we felt good about the quarter. And we feel -- honestly, our investments in China, we really feel good about those. The manufacturing piece helps legitimizes us -- our IT systems from a data protection standpoint have to be geared towards China. We're in good shape with that. We're assembling iTero there now. We feel great about our training centers, great about our treatment planning capabilities.

    所以——但我們對這一季的表現感到滿意。而且我們——坦白說,我們對在中國的投資非常有信心。製造端的布局有助於提升我們的正當性——從資料保護的角度,我們的IT系統也必須針對中國做相應配置;在這方面我們狀況良好。我們現在也在當地組裝iTero。我們對訓練中心非常有信心,對治療規劃能力也非常有信心。

  • So overall, we remain bullish on China, and we think that China will start to -- with the rest of the world, will start to recover in the second half of next year, too, and we expect to be a big part of that.

    總體而言,我們仍然看多中國,我們認為中國將會——和世界其他地區一起——也會在明年下半年開始復甦,而我們預期會在其中扮演重要角色。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Operator, we'll take one more question, please. And then we'll run over.

    接線員,請再讓我們回答最後一個問題。然後我們會稍微超時。

  • Operator

    Operator

  • Okay. Our last question comes from Nathan Rich with Goldman Sachs.

    好的。最後一個問題來自Goldman Sachs的Nathan Rich。

  • Nathan Allen Rich - Research Analyst

    Nathan Allen Rich - Research Analyst

  • Obviously, results over the past couple of quarters have been really strong. I guess when we look out to 2021, tough to know what happens with COVID, but hopefully, we'll start to get back to normal life later this year or 2022. I think as we look at where consensus is modeled, I think kind of high teens revenue growth, it seems like you still feel comfortable with the 20% to 30% target.

    顯然,過去幾個季度的結果都非常強勁。我想展望2021年,很難知道COVID會怎麼發展,但希望今年稍晚或2022年我們能開始回到正常生活。我認為從市場一致預估的模型來看,大概是營收高十幾%的成長;看起來你們仍然對20%到30%的目標感到有把握。

  • So do you feel like we should be expecting that type of growth in line with the long-term range off of this, like this new higher level of volumes that you're starting to see in the back half of this year?

    所以你們是否認為,我們應該預期在這之後的成長會與長期區間一致——也就是基於你們今年下半年開始看到的這個更高的量能水準?

  • Joseph M. Hogan - President, CEO & Director

    Joseph M. Hogan - President, CEO & Director

  • Nathan, that's -- we try to emphasize as much as we can, we feel very confident about those 20% to 30% range of growth and continuing to target 25% to 30% operating profit, too, in order to do that. So you'll see us -- in the investment rates that we -- John talked about, we're putting in place to drive that demand. So we make -- we remain committed to that modeled growth.

    Nathan,這——我們盡可能強調的是,我們對20%到30%的成長區間非常有信心,同時也會持續以25%到30%的營業利潤率為目標。為了做到這點,你會看到我們——就像John談到的投資比率——正在投入以帶動需求。因此,我們仍然致力於這個模型化的成長。

  • John F. Morici - CFO & Senior VP of Global Finance

    John F. Morici - CFO & Senior VP of Global Finance

  • And it starts with a vastly under-penetrated market and the investment opportunity, we talked about. We tried to give you kind of the breadth of all the different levers that we have to pull to be able to drive that return. And we continue to make that changes over time in terms of how we invest and where and so on, but that belief is still there. And when we make those forward investments, we're investing into that under-penetrated market that we think we can grow 20% to 30% in and do it at a 25-plus percent of margin rate.

    而這一切始於一個滲透率仍然非常低的市場,以及我們所談到的投資機會。我們試著讓你看到我們可以運用的各種槓桿的廣度,以推動那樣的回報。隨著時間推移,我們也會在投資方式、投資地點等方面持續調整,但那個信念仍然存在。而當我們做這些前瞻性投資時,我們是在投資於那個滲透率不足的市場;我們認為它可以以20%到30%的速度成長,並且以25%以上的利潤率來達成。

  • Shirley Stacy - VP of Corporate Communications & IR

    Shirley Stacy - VP of Corporate Communications & IR

  • Well, thank you, everyone, for joining us today. This concludes our earnings call. If you have any follow-up questions, please contact our Investor Relations department. And we look forward to following up with you in upcoming conferences and virtual events. Have a great day.

    各位,感謝今天加入我們。本次財報電話會議到此結束。如有任何後續問題,請聯繫我們的投資人關係部門。我們也期待在接下來的各項會議與線上活動中與各位再度交流。祝各位有美好的一天。

  • Operator

    Operator

  • This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation, and have a wonderful evening.

    今天的會議到此結束。您現在可以掛斷電話線。感謝您的參與,祝您有個美好的夜晚。